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CHAPTER I
INTRODUCTION
In the past five years, the genomics field has generated a prolific amount of sequence
data. Groups such as the 1000 Genomes Project and Complete Genomics have pioneered
next-generation data pipelines, including study design, data generation, variant calling, and
quality control of output data. These technological advances and collaborative projects have
made the study of low frequency variants increasingly achievable. It has become possible
to look beyond common variant polymorphisms typical of genome-wide association studies
(GWAS) and potentially explain additional trait variance using rare or low frequency vari-
ants (defined here as minor allele frequencies less than 1% and less than 5%, respectively).
Yet, even with increased data availability, progress toward understanding genomic vari-
ation and its association to common human disease lags behind. Scientists are hindered
in exploiting these laboratory advances because strategies for analyzing these data to uti-
lize their maximal potential are underdeveloped. In fact, the wealth of available data has
made distinguishing true scientific discoveries from the thousands of false discoveries even
more challenging. The growing disparity in rapidly advancing data collection vs. slowly
developing data analysis methods mandates a more concerted research effort to develop the
necessary analytical tools to successfully interpret the genotypic and biologic data. Success-
ful analyses will ultimately improve the prevention, diagnosis, and treatment of common
disease. Research that meets this critical challenge will include developing methods to an-
alyze the data and developing pipelines to integrate low frequency data from sequencing
with other “-omic” measures.
The study of low frequency variation on a genome-wide scale has been minimal prior to
the next-generation sequencing era. Due to the infancy of this research, none of the currently
available analytical methods are accepted as the “gold standard.” Previously developed
pipelines and tools used in GWAS are largely ineffective because rare variants have low
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r2 values and cannot be detected using a tag-SNP approach. According to the literature,
low frequency variants have larger effect sizes than common variant associations, are much
more prevalent than common variants, and have a higher proportion of nonsynonymous
variation. Therefore, they require special consideration when developing analytical tools to
study disease association [2, 3, 4].
Since low frequency variants are individually uncommon, large sample sizes are needed
to ensure that multiple copies of a variant of interest can be sampled [5, 6]. The study
design and cost of sequencing can make the required sample size prohibitive, particularly as
the minor allele frequency decreases below 1%. To increase the composite allele frequency
and analyze smaller sample sizes, collapsing methods can be utilized. Commonly referred
to as burden tests, variants in a specific genetic region can be binned into a single genetic
variable, which is then used for analysis [5]. An alternate collapsing strategy to the burden
test compares distributions of variants across the trait of interest. Nonburden tests do not
assume all variants binned together are causal or have the same direction of effect and can
model rare variant epistasis. Variations of burden and nonburden tests are described in
Chapter II. While nonburden tests are more powerful in cases with both protective and
deleterious variants or many noncausal variants, they are less powerful than burden tests if
a large proportion of binned variants in the same direction are truly causal or if the sample
size is relatively small [7].
Previous collapsing strategies have focused on a particular statistical test in a pre-
defined region rather than how to best group variants in informative regions. Agnostic
or uninformed binning approaches can often lead to a decrease in power when there are
variants with different directions of effect or too many neutral variants that mitigate the
signal. The most successful collapsing method groups variants likely to have an impact on
the function of a specific gene or genomic unit and compares the variant distribution or
composite genetic score distribution across the trait of interest.
The goal of this project is to address this major limitation of current rare variant asso-
ciation tests, uninformed binning. BioBin is a novel knowledge-guided collapsing method
which focuses on bin generation rather than association testing. By generating meaning-
ful bins with biologically related variants, the power of any statistical association method
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increases. In addition, BioBin provides the framework to create interesting and complex hy-
potheses by allowing multi-level bin generation using prior biological knowledge. While the
implementation facilitates burden tests most easily, BioBin is not coupled to any statistical
test. Users are able to use a variety of association tests, burden or nonburden methods, and
permutation strategies appropriate for the hypothesis and data being tested.
This thesis introduces the functionality of BioBin. First, the software is described
in detail with an explanation of many novel parameters and options specific to BioBin.
Second, extensive testing is presented using a variety of simulation parameters and a method
comparison. Third, application of BioBin to natural data sets is described to identify rare
variant burden differences between cases and controls.
Chapter II describes the genetic architecture of low frequency variants and the contri-
bution of low frequency variants to Mendelian and common complex disease. Chapter II
also discusses the evolution of low frequency variants and specifically why GWAS anal-
ysis pipelines fail in low frequency variant association tests. Lastly, the current state of
low frequency variant analysis is examined by reviewing available computation tools and
algorithms.
Chapter III details the development of BioBin and available options in the BioBin
package. This chapter presents an introduction and overview of resource requirements
for both BioBin and Library of Knowledge Integration (LOKI). Six software features are
characterized: custom knowledge input, multilevel feature binning, filtering strategies, loci
selection, optional inheritance patterns, and variant weighting. Lastly, statistical tests
commonly used with BioBin are briefly described. Portions of this chapter were derived
from “A Biologically Informed Method for Detecting Associations with Rare Variants” [8].
Chapter IV includes comprehensive type I error and power simulations under various
conditions. Described evaluations include different allele frequency weights, statistical meth-
ods, and power comparisons between BioBin and other methods. First, type I error was
evaluated using two continuous region simulations (simulating genes and pathways). Sec-
ond, simulations to study type I error for pathway-type analyses which have the potential
for dependent bins were performed. Lastly, correlation results between bin size and bin sig-
nificance and a few simulated power assessments were addressed. This chapter was partially
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adapted from a peer-reviewed manuscript, “BioBin: a bioinformatics tool for automating
the binning of rare variants using publicly available biological knowledge” [9].
Chapter V describes the application of BioBin to 1000 Genomes Project data. A
manuscript describing this work is in preparation at PLOS genetics, “Low Frequency Vari-
ants, Collapsed Based on Biological Knowledge, Uncover Complexity of Population Stratifi-
cation in 1000 Genomes Project Data.” In addition, some of the text from “Using BioBin to
Explore Rare Variant Population Stratification” was adapted for this chapter [10]. In order
to reveal the magnitude of low frequency population stratification, Chapter V describes
how pairwise population comparisons using the 1000 Genomes Project Phase I data were
performed to investigate differences in low frequency variant burden across multiple biolog-
ical features. Low frequency variant confounding is much more prevalent than one might
expect, even within continental groups. The proportion of significant differences in low fre-
quency variant burden is also dependent on the region of interest; for example, annotated
regulatory regions showed fewer low frequency burden differences between populations than
intergenic regions.
Chapter VI consists of two applications of BioBin on natural whole-exome data. BioBin
was applied to two data sets available from dbGaP: Kabuki syndrome (10 individuals)
and cystic fibrosis with chronic Pseudomonas aeruginosa infection (431 individuals). The
Kabuki analysis description and results were adapted from “BioBin: a bioinformatics tool
for automating the binning of rare variants using publicly available biological knowledge” [9].
The Kabuki sample is too small for adequate power, but the cystic fibrosis data analysis
identified several interesting genes for follow-up analyses.
In Chapter VII, the benefits and limitations of this approach are discussed. Chapter VII
also includes a discussion of the future of low frequency variant binning analyses and how
BioBin will be amenable to future improvements of genomic analyses. Finally, the funda-
mental considerations to advance genomic research are considered, particularly at the level
of sequence data analysis.
4
Terminology
Allele
Humans inherit one allele from each parent at every locus, resulting in a diploid state.
Each pair of alleles form the genotype at a particular locus. At the population level,
allelic variation at a locus is measurable as the number of different alleles (polymorphism)
present. If 99% of population is homozygous for TT at a genetic locus and 1% of population
is heterozygous with genotype TG, there are two alleles at this locus in the population, the
major allele is T and the minor allele is G.
Bin
Bins contain combinations of variants. Bins can be generated based on any number of
similarities. In this thesis, bins are often generated based on genomic location, e.g. gene
bins are formed based on the start and stop position of the gene. All of the variant loci
present in this gene are binned together and analyzed as a single unit.
Burden test
In this thesis, collapsing methods that use burden-type statistical analysis are referred to as
burden tests. Instead of retaining characteristics of each variant in the bin, the statistical
tests use a single summative value for all variants in the bin for each individual. The simplest
of these would be dichotomizing low-frequency variants for each individual (independent
variable designated as 0 if individual does not contain a low frequency variant and 1 if the
individual contains at least one low frequency variant).
Collapsing method
Collapsing methods refer to a general type of low frequency analysis, also called “binning”
methods, where low frequency variants are combined together based on some similarity
(genomic coordinates, functional significances, etc.) for analysis. The description of a
collapsing method refers to how the low frequency variants are combined. In the literature
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some collapsing methods also have a statistical test associated with the software. BioBin is
a collapsing method with multiple algorithmic components but without any incorporated
statistical test.
Gene
A molecular unit of heredity of a living organism. A gene is a defined region of DNA with
transcription start and stop sites coding for messenger RNA.
Linkage
Genetic linkage describes the way in which two loci located in close proximity on a chromo-
some are often inherited together. Loci in close proximity are more likely to be inherited
together. In contrast, loci located farther away from each other on the same chromosome
are more likely to be separated during recombination, the process that recombines DNA
during meiosis. The strength of linkage between two loci depends upon the distance, rates
of recombination, and functional interaction (might affect viability of offspring) in that
region of the chromosome. If two loci are in linkage equilibrium, they are inherited inde-
pendently in each generation. If two loci are in linkage disequilibrium, alleles at each locus
are inherited together more often than would be expected by random chance.
Locus
The location of a gene or particular sequence on a chromosome. The locus of a gene refers
to the start and stop positions of that gene. The locus of a variant is the specific genomic
coordinates of that variant in the genome (variant site). In this thesis, the term locus refers
to a single genomic coordinate where a variant occurs. Therefore, a single locus can refer
to the site of multiple allelic variants (polymorphic locus).
Mutation[11]
Change in genetic sequence that affects function. There are some that argue that the term
mutation should refer to any change in sequence below 1% and all other changes should be
called polymorphisms. However, this thesis only uses the term to describe variants with
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known effects on function, regardless of allele frequency. This is more consistent with the
definition of mutant from biology (wild-type versus mutant). The process of “mutation”
(verb) introduces novel variants to the population, but for a variant itself to be called a
mutation, it has to have known functional effects (harmful or protective). Literature from
the field of human genetics typically focuses on mutations that have harmful effects due
to the bias in research, which more often studies low frequency disease-causing variation
rather than variation that leads to improved health or longevity.
Nonburden test
Collapsing methods that use statistical analyses that retain characteristics of each variant in
the bin. These statistical tests often use vector-based methods to compare distributions of
variants across the trait of interest rather than using a single summative value. Nonburden
tests do not assume all variants binned together are causal or have the same direction of
effect and can model rare variant epistasis.
Polymorphism
A relatively benign change in genetic sequence. The term single nucleotide polymorphism
(SNP) is very popular in the literature and refers to more than one allele at a locus in a
population. Polymorphisms can cause variable phenotypes, but these changes are unlikely
to contribute to phenotypes that decrease fitness and have an allele frequency of an arbitrary
threshold of at least 1%.
Variant
Any change in genetic sequence at a particular locus. The term variant is used as a very
general and inclusive term relating to all genetic changes (single nucleotide changes, inser-
tions, deletions, copy number variation changes, etc.) of any frequency and of any functional
consequence (neutral, protective, damaging, or unknown). A single locus can have multiple
variants, e.g., if G is the referent allele, G→ C represents one variant and G→ T represents
a second variant at the same locus. In this thesis, the term variant typically refers to a sin-
gle nucleotide allelic change of any frequency or functional consequence. Unless otherwise
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specified, in the following chapters, “rare”, “low frequency” and “common” variants refer
to variants with minor allele frequencies ≤ 1%, ≤ 5%, and > 5% respectively.
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CHAPTER II
BACKGROUND
Since pioneering observations of genetic and evolutionary properties were reported by
Darwin and Mendel in 1859 and 1866, respectively, geneticists have been interested in
uncovering the secrets of inheritance, patterns of selection, distinguishing genetic and non-
genetic causes of traits or diseases, etiology of genetic diseases, and determining risk profiles
in individuals harboring variation [12, 13]. Later, the discovery of linkage and epistasis by
Bateson and autosomal recessive inheritance patterns of alcaptonuria by Garrod further
evolved the field of genomics [14, 15]. Present day genomics research utilizes unprecedented
technology and computational power, but the goal of uncovering disease associations and
understanding inheritance is much the same. This task is complicated by the numerous types
of genetic variation and genetic architecture, and interpretations of results are contingent
on understanding the landscape of genetic variation. This thesis focuses on the analysis of
low frequency variants; however, first characteristics of low frequency variants are reviewed.
It is important to consider the potential ways low frequency variants contribute to complex
disease, the evolution of low frequency variants, and how to translate these properties into
tools for studying low frequency variation.
Contribution of low frequency variants to disease heritability
Genome-wide association studies (GWAS) focus on common variants that often miss valu-
able information about epistatic (gene-gene, GxG) and gene-environment (GxE) inter-
actions, structural variants, and rare variants (RV) [16]. While researchers have been
able to attribute almost 11,000 variants from 1657 publications to over 80 diseases and
traits [17, 18], the estimated odds ratios for these variants are predominantly less than
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1.5 and a variable but small fraction of the estimated heritability has been explained. For
example, in a recent study of metabolic traits, Vattikuti et al. found previously published
common variants to explain between 25% (HDL trait) and 80% (systolic blood pressure
measurement) of estimated narrow sense heritability [19]. In the case of HDL and most
other traits, large proportions of heritability have yet to be explained. In an effort to eluci-
date additional heritability and to take advantage of the new sequencing technology, many
researchers are investigating, in particular, the effects of rare variants. Either because of
sheer number of rare variants or because of the effects of weak selection, rare variants are
thought to be more likely to be disease predisposing than common variants [20, 21]. It is
believed that rare variants can act alone, in concert with other rare variants, or together
with common variants. Bansal et al. describes many reasons rare variants likely influence
disease susceptibility [22]:
1. The recent population expansion resulted in a large number of segregating and po-
tentially functionally relevant rare variants.
2. Rare variants have been shown to be functional mutations in tumorigenesis.
3. There are many published examples of allelic heterogeneity (breast cancer: BRCA1,
cystic fibrosis: CFTR).
4. Functional assays have been performed in vivo for multiple rare variants and have
been shown to influence clinical phenotypes.
5. Rare variants have been associated with phenotypes in candidate gene studies.
One of the earliest and best characterized causal rare variant identifications occurred
in the study of cystic fibrosis (CF) in 1989 [23]. Kerem et al. performed an extensive
linkage analysis in CF patients with restriction fragment length polymorphisms to identify
a single locus, chromosome 7q31, corresponding to the CFTR gene. In the original paper,
the disease prevalence was stated to be 1/2000 live births in Caucasian populations, with
a mutant allele frequency of 2.2% [24]. Since this original publication and resulting ∆508
mutation identification, over 1000 other causative mutations have been identified to cause
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cystic fibrosis in the CFTR gene. Low frequency variants have been identified for several
other Mendelian traits using linkage studies and most recently, next-generation sequencing.
Approximately 1/2 to 1/3 of all known or suspected Mendelian diseases (approximately
7000) have been associated with a particular locus [25]. In the past, it has been difficult to
fully resolve missing heritability because linkage studies failed when the disease was too rare,
when too few family members were affected, when disease decreased reproductive fitness,
when the disease exhibited reduced penetrance, or when locus heterogeneity was present.
In addition, spontaneous instead of inherited mutations causing monogenic disorders were
impossible to study using linkage analysis [25, 26]. Next generation sequencing provides
resolution to a single base pair change and can be applied within pedigrees, across unrelated
individuals, in trios, and from sampling individuals from phenotype extremes. The user can
apply series of filters and deduce a list of potential mutations in a relatively short period of
time. In fact, in less than two years (2010-2011) over 27 studies were published identifying
rare variant loci for Mendelian traits/disorders [25].
Although dominant rare variants with large effect sizes (OR > 5) generally corre-
spond to Mendelian diseases with close to 100% penetrance, there is increasing evidence to
support a role for rare variants to contribute to risk of common, complex disease. Re-
cent studies have implicated rare variants with moderate effect sizes using phenotypes
such as obesity, autism, schizophrenia, hypertriglyceridemia, hearing loss, complex I de-
ficiency, type-1 diabetes, sporadic mental retardation, inflammatory bowel disease, sick
sinus syndrome, celiac disease, prostate cancer, Alzheimer’s, and overall cognition in the
elderly [25, 27, 28, 29, 30, 31, 32, 33, 34].
Evolution of low frequency variants
The use of indirect association tests popular in GWAS for rare variants is unlikely to be
powerful. In order to better understand why, it is important to consider the evolution of
rare variants. There is no defined allele frequency threshold to distinguish which variants
are considered rare and which variants are considered common. Dickson et al. identify rare
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variants using a minor allele threshold between 0.005 and 0.02 [35]. Gibson labels variants
as rare if the minor allele frequency is less than 1% [36]. Alternatively, others consider
variants rare that have minor allele frequencies less than 0.01-0.05 [7, 37]. In this text, rare
variants refer to variants with MAF ≤ 1%, low frequency variants refer to variants with
MAF ≤ 5%, and common variants refer to variants with MAF > 5%.
Rare alleles are observed for virtually every gene; Gorlov et al. estimate at least 2-3
rare variants per gene on average [20]. The expected number and distribution of disease
alleles in the population depend on mutation rate, selection and population ancestry. Rare
variants represent a considerable proportion of genome variation; Gorlov estimates up to
60% of SNPs in the genome are SNPs < 5% [20]. Many rare alleles are deleterious and
presumably persist in the population by recurrent mutation [1].
Population expansion
Demographic scenarios such as population subdivision with a change in migration rates over
time and admixture with archaic humans might have affected patterns of sequence variation
and linkage disequilbrium (LD). African populations fit a model of continuous population
growth, but other populations show a clear signature of a population bottleneck at about the
time of emergence from Africa [38]. A severe bottleneck has multiple genetic effects on the
population genetic structure. It changes the allelic frequency (genetic drift), increases the
average level of homozygosity (inbreeding), and causes correlations of allele frequencies be-
tween multiple alleles at the same locus (Hardy-Weinberg Equilibrium (HWE)) and among
variants at different positions (LD). Individuals of African descent have patterns of ge-
netic variation consistent with a larger long-term effective population size than populations
of non-African ancestry. The large effective population size is reflected in elevated levels
of diversity, elevated haplotype diversity, and reduced levels of linkage disequilibrium [1].
Rapid population growth and weak purifying selection have allowed ancestral populations
to accumulate an excess of low frequency variants across the genome. This affects genomic
analyses in two ways: it alters proportion of deleterious versus neutral variation expected
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in low frequency variants and population stratification.
Low frequency variants exhibit extreme population stratification [39]. Demonstrating
the magnitude of low frequency population stratification between two populations, Ten-
nessen et al. identified more than 500,000 single nucleotide polymorphisms (SNPs) using
15,585 protein-coding genes from 2,440 individuals. Of these SNPs, 86% had a MAF < 0.5%
and 82% were population specific between European Americans and African Americans [39].
Low frequency allele sharing between populations on the same continent were between 70%
and 80%. In contrast, low frequency allele sharing between populations on different con-
tinents were lower than 30% and variants were often unique to a single population. In
genomic analyses, this extreme population stratification can lead to higher false positives
and difficulty in replicating associations across genetic studies when not considered as part
of the experimental design for low frequency SNP analyses [40].
Common variants are often identified in more than one continental group, while rare
variants are often specific to one population. Common variants shared between African
and non-African populations are older and likely existed before the migration out of Africa.
Non-African populations tend to have less rare variants (more positive Tajima’s D test
statistic) than African populations. This can possibly be explained by a population size re-
duction (bottleneck) during which the rare variants were lost more quickly than the common
variants [38].
Effects of selection
The calculated intronic ratio suggested by Gorlov is calculated as the number of SNPs in
specific categories (nonsynonymous, possibly damaging, probably damaging, etc.) divided
by the absolute number of intronic SNPs and can be used as an approximate measure
of selection. Purifying selection drives variants to lower frequency, and positive selection
promotes high-frequency derived alleles. For variants with MAF <10% and particularly
<5%, the intronic ratio increases sharply suggesting a strong effect of purifying selection.
Comparing the different categories, the intronic ratio for probably and possibly damaging
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variants is even more increased, suggesting a stronger purifying selection against these
categories [20]. Therefore, the excess of rare variants in the human genome leads one to
conclude that many low frequency variants are functional and under the effect of purifying
selection. For example, cancer suppressors and oncogenes are under the pressure of purifying
selection. As a result, protein-damaging mutations in these genes have a lower frequency in
the population.
The actual distribution of allele frequencies in populations suggests that many segregat-
ing amino acid polymorphisms present at low frequency are mildly deleterious, less likely
to be eliminated by weak purifying selective pressure, and likely major players in common
disease susceptibility [1, 20]. For example, Nelson et al. found that in 202 drug target
genes, 2/3 of the low frequency variants were nonsynonymous mutations, a much higher
ratio than found for common variants. This ratio reflects the expected proportion given
random mutation and degenerate coding and also supports the theory that low frequency
variants are only weakly filtered by selection [4, 41]. Due to weak selection, low frequency
variants appear to be enriched for functional variation, including protein coding changes
and altered function [40]. In addition, low frequency variants represent a considerable pro-
portion of the variation in the genome due to recent explosive population growth [39]. Since
the allele frequency distribution is skewed towards more low frequency variants and many
of these are functional, a higher number of low frequency deleterious variants are expected.
These evolutionary conditions explain the prominence of disease-promoting variants at low
frequencies and reflect the balance between mutation and selection.
Evolutionary models
Human variation tends to fit the expectations of neutrality reasonably well, except that
human genes generally show an excess of rare alleles [1]. A common approach to testing the
standard neutral model is based on the Tajima’s D test. Under the standard neutral model,
the expectations of θW and of nucleotide diversity, pi, are equal [38]. Certain types of selec-
tion (selective sweep, where a rare variant was quickly favored and fixed in the population)
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or recent exponential population growth result in an excess of rare alleles, and Tajima’s D
statistic is negative [1, 38]. Alternatively, a positive value of D reveals a relative excess of
intermediate frequency alleles. This is expected under a model of population subdivision or
balanced polymorphism. This pattern suggests either some type of balancing selection, in
which heterozygous genotypes are favored, or some type of diversifying selection, in which
genotypes carrying the less common alleles are favored. This situation may also happen if
the sample population was formed from a recent admixture of two different populations [1].
Characteristics of low frequency variants
Calculating age of variants
Beyond theory, there are a few ways to estimate the age of a variant. As mentioned pre-
viously, low r2 values refer to more recent mutations. More precisely, allelic age can be
estimated from genetic variation among different copies (intra-allelic variation) and from
its frequency. Intra-allelic variation estimates follow the decay of LD. One must know the
recombination rate and expected frequency of the mutation at similar loci to calculate the
suspected generation time. Kimura and Ohta were the first to consider the relationship
between age and frequency (see Equation 1). Time is measured in 2N generations and p is
the observed allele frequency. For example, if the MAF is 2%, the estimated age is 32,000
years. One can use these methods together or contrast them to show evidence of natural
selection [42].
E(t1) =
−2p
1− p ln p (1)
Linkage disequilibrium in low frequency variants
Linkage disequilibrium (LD) between single nucleotide polymorphisms (SNPs) allows for
SNP tagging and indirect association testing. Linkage disequilibrium is defined as partic-
ular combinations of alleles at closely linked loci which occur more or less often than the
individual allele frequencies would predict. For example: imagine a locus with two alleles,
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Table 1. Example of linkage disequilibrium. Adapted from Hartl et al. [1]
STEPS
ALLELE ALLELE POSSIBLE
(SITE 1) (SITE 2) GENOTYPES
1. Ancient monomorphic alleles A B AB
2. A mutates to a Aa B AB, aB
3. B mutates to b in chr carrying aB Aa Bb AB, aB, ab
A and a. The Hardy-Weinberg Equilibrium (HWE) principle states (assuming all assump-
tions are met) that the genotypes AA, Aa, and aa are expected to be p2A, 2pAqa, and q
2
a,
respectively (where p and q represent the major and minor allele frequencies). Thus, the A
allele is in random association with the a allele. The same could be said for another locus
containing B and b alleles, where the B allele is in random association with the b allele (see
Table 1). When the alleles of these two loci are not linked, the frequency of a particular
combination of alleles equals the product of their respective allele frequencies. This is called
linkage equilibrium. When the alleles of the A locus are linked with alleles of the B locus,
the loci are in linkage disequilibrium.
The frequency of recombination (r) between loci is important because it determines the
rate towards linkage equilibrium. The frequency of recombination is necessarily r = 0.5
when two loci are on different chromosomes and r = 0 when the two loci are too close
together for a break to occur between them. The farther apart two loci are, the more likely
recombination between the loci becomes. The genotypic frequencies are related to the allelic
frequencies in the previous generation and D is the difference between the frequency of given
haplotype (observed) in the previous generation minus the frequencies of the A and B alleles
in the previous generation (expected). See Equation 2 for one example haplotype.
D = PAB − pApB (2)
Dn = (1− r)nD0 (3)
Dn is the value of D in the n
th generation, thus it shows the decay of LD over generations
(time) due to recombination. The term (1 − r)n goes to zero as n becomes large (see
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Equation 3); the smaller the value of r the slower the rate towards equilibrium. Dn will
go to zero unless there are other factors to offset the decrease to linkage equilibrium (e.g.
nonrandom mating or other violations of HWE). The decay of LD, which can be estimated
by exponential decay, is shown in Figure 1 for different recombination frequencies [1].
Three things can affect linkage disequilibrium:
1. Recombination. Recombination occurs at hotspots across the genome and breaks up
LD. The rate of approach to linkage equilibrium depends on the rate of recombination
in genotypes heterozygous for both loci (see Equation 3). Inbreeding reduces the
frequency of heterozygous genotypes so that LD is maintained and recombination is
minimal.
2. Gene conversion may replace a small integral part of a conserved segment, producing
localized breakdown of LD, whereas markers on each side continue to show LD.
3. Population history. The older the population, the shorter the conserved segments.
LD is more extensive and of longer range in populations derived from recent founders.
LD can result from mixing subpopulations with different allele frequencies. If subpop-
ulations permanently mix and undergo random mating, LD is expected to decrease
according to the recombination rate, r, per generation. Similarly, inbreeding reduces
recombination because it reduces the frequency of the double heterozygotes, which
are essential for recombination to take place.
D depends on the allele frequencies, so it is often normalized by dividing D by the
theoretical maximum for observed allele frequencies. To calculate D′ and r2, see Equation 4,
Equation 5, and Equation 6 [1].
D′ =
D
Dmax
(4)
where
Dmax =

min (pAqb, qapB) when D > 0
min (pApB, qaqb) when D < 0
(5)
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Figure 1. Linkage disequilibrium between genes gradually disappears when mating is random, pro-
viding no other processes are present. The rate of approach to linkage equilibrium depends on the
recombination frequency between the genes. Adapted from Hartl and Clark 2006 [1].
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Table 2. Examples of r2 and age of mutation adapted from Hartl and Clark [1].
AGE OF
MUTATION
GENOTYPE
FREQUENCIES
CALCULATED
r2
b arose early in a lineage PAB = 0.5 PAb = 0 r
2 = 0.96
PaB = 0.01 Pab = 0.49
b arose much later in a lineage (more recent) PAB = 0.5 PAb = 0 r
2 = 0.01
PaB = 0.49 Pab = 0.01
r2 =
D2
pAqapBqb
(6)
D′ is a normalized measure of LD and it is mostly influenced by recombination. For
example, if D′ = 0.50, the amount of disequilibrium between the SNPs in the two loci is
about 50% of its theoretical maximum. For any given D′, r2 can take any value between 0
and D′2. The range of r2 is due to the fact that it also depends on the allele frequencies.
r2 is a measure of linkage disequilibrium, but it captures when/where in the genealogy of
the haplotypes the mutation occurred. For example, there are two ancient monomorphic
alleles A and B at two sites. Over time, the A allele mutates to a and B mutates to b.
The possible genotypes following each of these steps is shown in Table 1 [1]. After the third
step (B mutation), notice there is no Ab genotype. It will remain at 0% frequency in the
absence of recombination or recurrent mutation. Because of the missing haplotype, D′ = 1
and the value of r2 depends on the timing of the B → b mutation (see Table 2). The r2
value relates to the age of the mutation, lower values refer to more recent mutations.
According to simulations performed by Kruglyak, the rapid decay of LD with distance is
a consequence of the relatively ancient origin of most common variants. Variants observed
at 10% frequency tend to be of a more recent origin, but also date almost exclusively to the
time of expansion or earlier (assuming this is a neutral variant). Rare variants often make
only three haplotypes with common SNPs, in this case, r2 can be close to zero (depends
on age of variant) while D’ is 1 [1, 43]. Therefore, r2 is the more reliable measure of LD
when considering rare variants. The value of r2 depends on the allele frequency difference
between the two loci. The genotyped SNP that tags the most variants from the causal SNP
(has the highest r2) is the SNP with the lowest MAF in which the minor allele is coupled
19
Table 3. Maximum r2 and expected odds ratios (OR) between a rare causal variant and common
genotyped SNP with an odds ratio of 1.1. Adapted from Wray et al. [43]
Freq. of
Estimate
Freq. of genotyped SNP
causal variant 0.05 0.10 0.20 0.30 0.40 0.50
0.005
r2 0.10 0.05 0.02 0.01 0.01 0.01
OR 2.0 3.0 5.0 7.0 9.0 11.0
0.01
r2 0.19 0.09 0.04 0.02 0.02 0.01
OR 1.5 2.0 3.0 4.0 5.0 6.0
0.02
r2 0.39 0.18 0.08 0.05 0.03 0.02
OR 1.3 1.5 2.0 2.5 3.0 3.5
with the rare causal variant. The possible LD structure between rare and common variants
is detailed in Table 3 [43].
Linkage disequilibrium is a result of history; it reflects shared ancestry of haplotypes
present in any population [1]. The presence of LD can be explained by LD in a founding
population that has not had time to dissipate due to low frequency of recombination or
because of natural selection [1, 38]. Random mating reduces haplotype blocks (LD) [1].The
International HapMap Consortium defined the ancestral chromosome segments in four hu-
man populations and catalogued markers that could be used in GWAS as tag SNPs [20, 44].
The commonly employed strategy of indirect association testing relies on the association
between disease and SNPs near a true causal variant, where the associated SNP and causal
variant are in LD. This allows for a dense map of tag SNPs to scan the genome for regions
associated with a trait of interest [44]. As mentioned before, this has led to the discovery
of many common SNPs associated with disease.
Current methods to analyze low frequency variation
There are three categories of analysis possible for rare variants in a whole-genome study:
direct association testing, indirect association testing (utilizing LD), and collapsing meth-
ods. Direct association testing is plausible, but unlikely to be effective in current common
study sizes where the total sample size is < 1000 individuals because rare variants will be
scarce and contribute small numbers to the analysis which necessitates cautious interpre-
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tation [45]. It is difficult and extraordinarily expensive to ascertain large enough data sets
to acquire sufficient numbers of cases that carry the same causal rare variant and to be
able to detect a difference in allele frequency when the MAF is so low [20, 21, 22, 46, 47].
As an example, Nejentsev et al. was able to report a rare variant association with a
MAF 0.46% in cases and 0.67% in controls using 17,730 individuals [48]. This is much
larger than the current size of most sequencing studies due to cost. A single exome
with 50x coverage can cost between $850-$1000 US dollars for direct to consumer pric-
ing (https://www.23andme.com/exome/, http://www.axeq.com/axeq.html; accessed July
17, 2013) and approximately $500 US dollars for in-house rates within an institution
(http://vantage.vanderbilt.edu/pubutils/ngscalc.html; accessed July 17, 2013). For a single
in-house whole-genome sequence (50x coverage) without analysis, the cost is over $8000 US
dollars. The prices are steadily falling for next-generation sequence data, but the costs of
a study of any reasonable size can quickly exceed $100,000. The prohibitive costs make
single variant association testing unfeasible for variants with low minor allele frequencies.
Ignoring this limitation with small sample sizes could lead to unstable estimates of rare
variant effects on disease and be uninformative [49].
Performing indirect tests of association with rare variants will lead to dubious interpre-
tation of results. Rare variants can be in LD with other variants; rare haplotypes exist and
can be associated with disease [50]. However, indirect association testing assumes low-level
allelic heterogeneity and assumes that the variants are common [21, 44]. Rare variants have
low MAF and low r2 values and thus exhibit poor tagging properties with common variants
(see Table 3) [21, 51]. Inappropriate indirect SNP association testing runs a high risk of
false-negative results because rare functional variants can be inadequately tagged. For vari-
ants of lower frequency, the decay of LD is similar to common variants, but the maximal
level of LD at zero recombination is lower due to the difference in frequency between the
variant and the associated SNP allele. To successfully use tag SNPs for indirect association
testing, it is best to match the allele frequency of the variant and associated SNP allele.
Common variants can be detected with single markers using a tag SNP approach, whereas
lower-frequency variants require haplotype analyses or binning for association testing [44].
Haplotype analyses are very sensitive to population stratification, haplotype structure, and
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matching allele frequencies and should be utilized with caution [46].
Recently there has been some interest in synthetic associations. Synthetic associations
are a particular type of indirect association, specifically, the association of a genotyped
common marker resulting from multiple unobserved low-frequency causal variants [35, 43].
Some authors believe rare variants can cause synthetic associations with real risk effects
several-fold stronger than what is credited to a tagged common variant [3]. Therefore,
variance explained by the causal variants is much higher than what is seen in the associated
SNPs because the genotyped SNPs have not tagged the causal variants with great precision.
Synthetic associations are unlikely responsible for signals found in GWAS. Given the
required effect sizes (due to poor tagging), it is unlikely that synthetic associations explain
common variant associations [43]. These hypothetical rare variant effect sizes are so large
they would have been almost certainly picked up in linkage studies (see Table 3). Although
very common associated SNPs are unlikely to be causal, they most likely tag causal SNPs
with similar allele frequency and are unlikely to represent synthetic associations [43].
Searching for genes with an enrichment of rare variants even in a low number of se-
quenced genomes is more productive [3]. Given the restrictions of available sample sizes,
binning methods are likely to be the most powerful and effective methods to identify causal
rare variants. Most often a single variant is likely too rare to completely explain the ob-
served prevalence of a trait of interest, particularly common, complex traits. However, the
high proportion of rare variants across the genome, presence of allelic heterogeneity, and
presence of locus heterogeneity can explain additional prevalence of a trait [20].
To date, most sequence analysis tools use standard analytical methods to reduce the
search space. One standard method is to use family data which allows the analyst to exploit
transmission patterns to filter the data [52]. This strategy is effective but not applicable
to data sets without family information. Another technique is to perform a candidate gene
study and collapse rare variants into bins in order to combine association signals. Collapsing
methods are favorable for the following reasons:
1. Applies to case-control studies
2. Applies to whole-genome sequence data
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3. Potentially enriches association signals by combining otherwise underpowered rare
variants
4. Reduces the degrees of freedom in the statistical test
Collapsing methods, which test cumulative effects of rare variants in genetic regions, can
be classified based on the type of statistical test used, either burden or nonburden tests [7].
Burden tests
Instead of testing each variant independently, variants that fall below a specified MAF
threshold can be collapsed into a single comprehensive variable for analysis. The burden
tests described below are unique approaches that combine variants’ weights or manage bins
using different MAF thresholds or genomic boundaries. The first researchers to describe
a burden test collapsing approach were Morgenthaler and Thilly in 2007 [53]. Their co-
hort allelic sums test (CAST) calculates the sums of allelic mutation frequencies in cases
versus controls and applies a statistical test to determine if the difference is statistically
significant. The CAST method assumes that rare variants have the same magnitude and
direction of effect. Because the method uses a chi-square statistic, it is less than ideal be-
cause it does not easily incorporate covariates, cannot be used in quantitative phenotypes,
and does not measure the direction of association [22]. One year later, Li and Leal de-
veloped a similar method, the combined multivariate and collapsing method (CMC). The
CMC method uses a multivariate statistical test and permits combined analysis of rare and
common variants [21]. The CMC method has improved power over CAST, presumably be-
cause functional information (direction of effect) was incorporated and because the method
can be implemented in a regression framework [54].
The next group of published collapsing tests introduced the idea of individual variant
weighting. Witte describes two approaches to weighting: a priori weighting or empirical
weighting [5]. A priori aggregation methods can be used in many ways; the CAST method
applies an a priori weight because it requires “all or nothing” bins. If an individual has
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one or more variants, the comprehensive genetic variable is the same. Another sensible
way to weight variants includes using properties such as minor allele frequency cutoffs, or
nonsynonymous versus synonymous changes. Madsen and Browning proposed a collapsing
method using a priori weights, each variant is weighted using its allele frequency, a com-
prehensive genetic score is calculated and then a rank sum test between cases and controls
is performed [55].
Other burden tests use empirical weights to aggregate variants, essentially utilizing ex-
ternal information about the potential functionality of variants, such as, variable minor
allele frequency cutoffs and directionality of effect [5]. Price et al. propose a method to
optimize the grouping of rare variants using a variable-threshold approach based on allele
frequency [56]. Similarly, Fang et al. propose a pooling method using a threshold of risk
measure instead of allele frequencies to build bins with the most powerful association sig-
nal [57]. Hoffman et al. utilize a step-up approach to iteratively add variants to a bin only if
it improves the association signal [49]. Several other methods cleverly incorporate functional
data to guide collapsing and use a regression framework for statistical association [58].
Burden tests are notoriously less powerful when variants binned together have opposing
directions of effect [7, 37]. It is important to employ filtering strategies and attempt to
create bins with functional variants with the same direction of effect.
Nonburden tests
Instead of assessing the cumulative effects of variants in a bin by summarizing the genetic
score into a single value, nonburden tests investigate the variance distribution of allele fre-
quencies. The first published nonburden test was the C-alpha test. In case-control data,
it compares the expected variance to the actual variance of the allele frequency distribu-
tion [59]. Nonburden tests are often more powerful in bins where variants have different
directions of effect. Kernel based tests, such as SKAT and SKAT-O, improve upon C-alpha
because they can be implemented in a regression framework (rather than requiring permu-
tation), allow for easy covariate adjustment (including controlling for population stratifica-
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tion), and can be applied to dichotomous and continuous phenotypes [37, 7]. The kernel
association test aggregates individuals’ variant-score tests statistics with weights when SNP
effects are modeled linearly. Then they aggregate associations between variants and pheno-
types using kernel matrix. SKAT tests can also incorporate local correlation substructure,
weights, and can allow epistatic effects [37].
Nonburden tests are often overly conservative, particularly in small study sizes and when
the large majority of variants are truly causal. SKAT-O improves upon SKAT because
it allows correlation between variant regression coefficients, which improves power when
binned variants are in the same direction of effect [7].
Conclusions
As with linkage and GWAS, the number and penetrance of alleles affecting disease risk, i.e.,
the genetic architecture of a disease, directly affect the strategy for identifying polymor-
phisms that modulate disease susceptibility [20]. One must be careful to match cases and
controls since overrepresentation of rare variants in a specific ethnic group may complicate
the interpretation of association analyses of such variants. Even though there are many
available testing strategies, statistically significant mutations, multiple mutations that are
functional and co-segregate with disease, de novo mutations, and/or model organisms are
required to prove a link between variation in these genes and disease [47].
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CHAPTER III
BIOBIN SOFTWARE
Many recent publications detail collapsing approaches for low frequency or rare vari-
ant association tests. These methods build bins of multiple rare or low frequency variants
across pre-defined regions and use a statistical test to detect an association between the
presence/absence, number, or the distribution of low frequency variants and case/control
status. BioBin contributes novelty to the field of low frequency variant association testing
by focusing on defining regions rather than demonstrating the use of a particular statis-
tical test. Most available software packages include a default statistical test and do not
provide any guidance or assistance in defining regions for binning. For a given dataset and
hypothesis, there are different and sometimes multiple statistical tests that are appropri-
ate. In addition, novel statistical tests for binning methods are published frequently in
the literature, and the freedom to choose a specific test for an analysis is often preferable.
There are explicit situations that require the use of regression analysis (logistic, linear, or
polytomous), Fisher’s exact test, or permutation of unique statistical test, etc. A simple
analytical pipeline for low frequency variant analyses using BioBin is shown in Figure 2.
Overall, the most powerful collapsing analysis to detect associations with low frequency
variants will use a method to define bin boundaries in a way that will combine low frequency
variants with similar functional properties and apply the most appropriate statistical test.
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Figure 2. Pipeline for BioBin analysis. Blue squares correspond to data, green hexagons correspond
to bioinformatic or statistical method applications.
BioBin resource requirements
BioBin is a standalone command line application written in C++ that relies on a locally
built Library of Knowledge Integration (LOKI) database (see later section describing LOKI)
to create knowledge based bins. Source distributions are available for Mac and Linux op-
erating systems and require minimal prerequisites to compile. In the BioBin distribution
download, included tools allow the user to create and update the LOKI database by down-
loading information directly from source websites.
BioBin computational requirements scale primarily according to the number of loci in
the study. To demonstrate this, the population size and number of loci has been varied
in the input variant calling format (VCF) file of the 1000 Genomes Project Phase I low
coverage data to assess the resource requirements of BioBin [60]. Over 10 replicates, Figure 3
shows that bin generation is highly correlated to the number of loci in the study and
bin generation drives the memory and time usage. The number of individuals in a study
does not have a large impact on resource requirements, but does increase the size of the
input VCF file and thus time it takes BioBin to read the input VCF file. Even with
large datasets, BioBin can be run without access to specialized computer hardware or a
computing cluster; however, the number of binnable low frequency variants is the primary
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driver of memory usage. BioBin is open-source and publicly available on the Ritchie lab
website (http://ritchielab.psu.edu/ritchielab/software/).
Library of Knowledge Integration database (LOKI)
Harnessing prior biological knowledge is a powerful way to inform collapsing feature bound-
aries. BioBin relies on the Library of Knowledge Integration (LOKI) for database integra-
tion and boundary definitions. LOKI contains resources such as: the National Center for
Biotechnology (NCBI) dbSNP and gene Entrez database information [61], Kyoto Encyclope-
dia of Genes and Genomes (KEGG) [62], Reactome [63], Gene Ontology (GO) [64], Protein
families database (Pfam) [65], NetPath - signal transduction pathways [66], Molecular IN-
Teraction database (MINT) [67], Biological General Repository for Interaction Datasets
(BioGrid) [68], Pharmacogenomics Knowledge Base (PharmGKB) [69], Open Regulatory
Annotation Database (ORegAnno) [70], and evolutionary conserved regions from UCSC
Genome Browser [71].
LOKI provides standardized interface and terminology to disparate sources, each con-
taining individual means of representing data. The four main concepts used in LOKI
are positions, regions, groups, and sources. The term position refers to single nucleotide
polymorphisms (SNPs), single nucleotide variants (SNVs) or low frequency variants. The
definition of region has a broader scope, any genomic segment with a start and stop position
can be defined as a region, including genes, copy number variants (CNVs), insertions and
deletions, and evolutionary conserved regions (ECRs). Sources are databases (such as those
listed above) that contain groups of interconnected information, thus organizing the data in
a standardized manner. For example, BioGrid ID:468346 defines a group from the BioGrid
data source. This group contains the following regions: HMGB1P1, CTCFL, and PRMT7.
LOKI is implemented in SQLite, a relational database management system, which does
not require a dedicated database server. The user must download and run installer scripts
(python) and allow for 10-12 GB of data to be downloaded directly from the various sources.
The updater script will automatically process and combine this information into a single
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database file (∼6.7 GB range). A system running LOKI should have at least 50 GB of disk
storage available. The script to build LOKI is open source and publicly available on the
Ritchie lab website (http://ritchielab.psu.edu/ritchielab/software/). Users with
knowledge of relational databases can customize their LOKI database by including or ex-
cluding sources, including additional sources, and updating source information as frequently
as they like [Pendergrass et al., in preparation].
BioBin software overview
BioBin options can be configured via configuration file or command line input, which is
helpful when developing low frequency variant analysis pipelines. Even in the same data,
one might consider testing multiple hypotheses. For example, one could run BioBin with
binning boundaries based on genes and then make a few small changes to the configuration
file to run pathway binning analyses. BioBin also includes several novel features and options
for evaluating low frequency variants, those are described in the Software Features section.
Input files
To run BioBin, the user must have a locally built LOKI database and two study files:
1) variant calling format file (VCF) and 2) phenotype file. The LOKI database is de-
scribed in the previous section and detailed instructions can be found in the BioBin manual,
which is available on the Ritchie lab website (http://ritchielab.psu.edu/ritchielab/
software/). At this time, BioBin only accepts zipped and unzipped VCF files as study
input. A single input VCF file should include all of the relevant individuals and study vari-
ants. The most recent genome build is preferred for genome coordinates to match LOKI
information, but BioBin contains an internal algorithm derived from LiftOver to trans-
form variants from older builds to the newest build if necessary [71]. Lastly, the user must
include a phenotype file, a simple file with two columns indicating the sample identifiers
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Table 4. Example phenotype input file
ID PHE
ID1 0
ID2 0
ID3 1
ID4 1
ID5 0
(string value) found in the VCF file and corresponding phenotype (floating point value).
Most of the current tests have focused on binary outcomes, but categorical or continuous
outcomes are acceptable as phenotypes. The user needs to specifically indicate the desired
“control” group to determine allele frequencies and to determine which variants in the data
are binnable. For binary traits, one group should be designated as the control group. For
quantitative traits, a single group can be designated as controls or all individuals can be
considered together to determine binnable variants. An example phenotype file with binary
outcomes is shown in Table 4. Other input files are optional and described in further detail
in the Software Features section.
Output files
There are two main output files produced by BioBin: bins report and locus report. The
bins report provides information on bins generated by BioBin. An example bins report
output file is shown in Table 5. Lines 1-6 include the file header and summary information
for each bin. Each line after 6th row corresponds to an individual in the study. After ID
and Status columns, columns i = 3..N represent all of the bins generated by BioBin. The
values in a cell correspond to the contribution of variants of each individual (row) to the
bin (column).
The summary rows summarize the variants and loci in each bin. Row 1 contains the total
number of variants found within a bin. Row 2 represents the total number of loci binned
together. With regard to the values in rows 1 and 2, a locus corresponds to the physical
location of the variant. A single locus can represent multiple variants because there can be
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Table 5. Example bins report output file
ID Status TTLL10 WRAP73
Total Variants -1 32 63
Total Loci -1 5 5
Control Loci Totals -1 5 5
Case Loci Totals -1 5 5
Control Bin Capacity -1 134 172
Case Bin Capacity -1 130 130
NA06984 0 0 1
NA06985 0 0 0
NA20504 1 0 1
NA20506 1 0 0
multiple alleles at a particular location in the population. Rows 3 and 4 exclude loci for
which data are entirely missing from either the case or control populations. Rows 5 and 6
show the total bin capacity for either the cases or controls. The capacity is defined as the
absolute maximum number of variants that could be contributed to a given bin.
The locus report contains information about the variants and bin statistics, but does
not contain any information about individuals in the study. Each line corresponds to a
locus in the study, similar to the VCF file. A sample of the locus report output file is shown
in Table 6. Columns 1, 2, and 3 identify each locus. Column 4 represents the alleles and
their frequencies, as calculated from the designated control population. A pipe (|) character
separates individual alleles, and the allele and frequency are separated by a colon (:). The
alleles are ordered from most frequent to least frequent, and the minor allele frequency
(MAF) is defined to be the frequency of the second most common allele. Column 5 refers
to the non-major allele frequency in the case population. The non-major allele frequency is
defined to be the frequency of all alleles other than the most common allele in the control
population. Column 6 represents the status of the locus. If the minor allele frequency is
below the threshold for binning, this column will be 1, if the minor allele frequency exceeds
the threshold, it will be 0. Column 7 lists all genes that contain the locus separated by a
pipe (|). Column 8 lists the bin names that contain the locus, again separated by a pipe (|).
Generation of any of these reports or a few additional reports that include allelic or
bin statistics can be turned on or off at the user’s request using options available on the
command line or in the configuration file. For information on additional reports, the BioBin
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manual is available on the Ritchie lab website (http://ritchielab.psu.edu/ritchielab/
software/).
BioBin software features
In addition to flexible and biologically informed binning strategies, several important fea-
tures have been implemented to improve upon existing collapsing approaches. These param-
eters include: user-defined or customized knowledge, adjustable multi-level feature types,
various filtering strategies, flexible loci selection, and individual variant weighting.
Customized knowledge
The LOKI database contains diverse and comprehensive knowledge from many databases,
which together provide variant details, region annotations, and multiple region or group
relationships (e.g. pathways or protein interactions). To accommodate a wide-variety of
analyses, the user can choose to include or exclude any source available in LOKI from the
command-line or configuration file. If provided by the user, BioBin accessible knowledge
can also be expanded to include sources of knowledge outside of LOKI. For example, if a
user wishes to bin specific regions based on his/her research knowledge that is not described
in any public database loaded into LOKI, there are several options to include this novel
information for a BioBin analysis. The first option is to add this knowledge to the LOKI
database. This requires a relatively advanced understanding of the LOKI framework and
SQL relational databases, but LOKI is open-source and can be modified on a local machine.
A second and likely easier option is to input custom region files to transiently define bin
boundaries. Custom feature files can be used in place of or in addition to LOKI knowledge.
An example of a custom feature file is shown in Table 7.
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Table 7. Custom region feature file.
Chrom ID Start(bp) Stop(bp)
9 Region1 1384729 1673929
13 Region2 14940582 16392837
18 Region3 27361833 29877254
22 Region4 188726 1208327
Multi-level feature binning
The most important component of BioBin is the ability to bin at multiple levels of biological
knowledge. Example binning strategies can be seen in Figure 4. One can create gene-based
bins for an exome study, but very quickly change the configuration file to collapse genes
together to investigate evidence of protein-protein interactions. Using hierarchical biological
relationships and optional functional or role information, BioBin can create bins based on
many unique binning guidelines.
As a standard in the current iteration of LOKI, NCBI dbSNP and NCBI Entrez Gene
have been selected as the primary sources of position and regional information due to
the data quality, reliability, and clearly defined database schema. These sources also most
closely correspond to the region and group IDs provided by other database sources integrated
into LOKI.
In addition to binning variants based on knowledge, BioBin also provides an option to bin
variants that do not associate with any available knowledge. These are known as interregion
bins, or if generated between gene features, intergenic bins. After feature selection using
LOKI and/or external custom files, interregion bins can be created using a configurable
width parameter (in kb). These bins catch variants that do not fit into the user-defined
or biologically defined feature types (see intergenic bin labels on Figure 4). For example,
if one were testing low frequency burden differences between two groups across genes, all
variants in genes would be collapsed into respective gene bins, and variants outside of gene
boundaries would be binned based on genomic location in intergenic regions.
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Table 8. Custom region feature file.
Chrom ID Start(bp) Stop(bp)
10 DEL 100010909 100010909
11 DEL 99715682 99715682
16 DEL 97443 97443
18 DEL 13029986 13029986
Filtering strategies
In published whole-exome studies, a series of filters are often applied to remove neutral
or presumably low impact variants. Frequently this is accomplished by excluding variants
found in datasets such as 1000 Genomes Project or excluding variants with certain proper-
ties, i.e. synonymous or predicted neutral variants. Similar to the custom region knowledge
files described previously, BioBin accepts custom role files, which contain single variant or
region annotations. These custom role files can be used to exclude or specifically include
variants for a binning analysis. For example, one could use a role file to exclude variants
based on the 1000 Genomes Project. Alternatively, with the same role file and slight pa-
rameter change, one can study variants exclusively present in the 1000 Genomes Project.
This functionality is particularly useful if the user wants to filter based on protein coding
variants or predicted damaging variants using an annotation tool such as Polyphen-2 or
SIFT [72, 73, 74]. Table 8 shows an excerpt of annotated variants from the 1000 Genomes
Project using Variant Effect Predictor Tools (VEP), an annotation tool that provides SIFT
and PolyPhen-2 predictions [72, 73, 74, 75]. For example, if using a role file similar to one
found in Table 8, BioBin could create gene feature bins containing only variants predicted
to be deleterious or damaging (DEL).
Locus selection
In the binning method literature, it is common for studies to calculate allele frequencies in
unaffected individuals to determine if a locus is binnable, i.e. less than the MAF binning
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threshold. However, constraining binnable loci based only on controls leads to selection
bias and an increase in type I error, which worsens in large bins. In this thesis, the term
locus refers to a strict chromosome coordinate or position and the term variant describes
alleles at that locus. The minor allele at a given locus is determined from the second most
frequent allele in the control group.
Three parameters have been implemented in BioBin to manage type I error, reduce
selection bias, and increase flexibility in selecting binnable loci. The first option is a con-
figurable MAF binning threshold. Binning strategies are applied to low frequency variants,
where the user defines “low frequency.” Price et. al proposed a variable threshold approach;
Price suggested that a single minor allele frequency threshold does not apply to all stud-
ies [76]. Although this is not available as an automatic optimization in BioBin, the MAF
binning threshold can be tested and optimized by the user for his/her study data.
The second option, labeled Rare-Case-Control or “RCC,” addresses how BioBin handles
the minor allele frequency-binning threshold in two groups. When RCC is enabled, if the
variant is low frequency in either group, the locus is binnable. This does not change which
allele is considered the minor allele, the minor allele is annotated using unaffected group
allele frequencies, but it does increase the number of binnable loci because it includes specific
sites (or loci), which have a low frequency variant in cases and not in controls.
To illustrate the effect of “RCC,” the CEU population from 1000 Genomes Project data
was randomly divided into cases and controls. In Figure 5, each line corresponds to a MAF
binning threshold. At a very low binning threshold (MAF≤ 0.02), there is a distinct increase
in bins with small p-values (red line). The low MAF threshold constricts the contribution
of variants by each control to only one variant, whereas, each case can contribute one or
more variants. In larger bins (bins containing more loci), this slow accumulation of variants
in cases quickly leads to significance. However, when the RCC parameter is turned on, the
p-value distribution is more uniform and selection bias is reduced.
A Kruskal-wallis test was run to determine if the mean p-value was the same in groups
with varying loci per bin (accomplished by increasing the MAF binning threshold). Without
using the RCC option, the Kruskal-wallis p-value was 2.2e−16 (see Figure 5a). Thus, at least
one of the three MAF threshold groups had p-values that differed from the others more than
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chance alone. In Figure 5b, the RCC option was utilized and the p-value was no longer
significant (p-value = 0.288). When RCC was on, the difference between the three groups
was no longer detectable. Therefore, adding the RCC option decreases error and specifically
decreases the correlation between bin size and significance.
Although it is not advisable to perform genomic association analyses in low frequency
variants in study data with considerable heterogeneity in ancestral background, there are
still loci with considerable allelic heterogeneity within continental groups [4, 5, 6]. The third
parameter option concerns choosing the minor allele. In a recent population comparison,
switching the group status (case/control) changed the results by 1-3%. The last option for
loci selection,“overall-major-allele,” addresses this problem (denoted as “OMA” in Table 9).
This option was added to allow BioBin to look at affected and unaffected groups before
determining which alleles are the major and minor alleles. When the overall-major-allele
option is turned on, the major allele is designated by the overall highest frequency allele.
In Table 9, each line corresponds to alternative ways a single variant would be handled
under permutations of these options for 100 affected individuals (MAF=0.3) and 100 unaf-
fected individuals (MAF=0.05). Generally, controls are assigned as individuals unaffected
by the phenotype; however, to illustrate RCC and OMA options, the control group alter-
nates between affected and unaffected individuals. Examples A-D show the function of the
rare-case-control option. In example A, the variant is not rare enough in the designated
control group to be binned. Under the same parameters, if the unaffected individuals are
designated as controls, the variant is binned because it meets the minor allele frequency
threshold (example B). Most often, it is not beneficial for results to change based on control
designation. Examples C-D show how the variant is binned regardless of control group
designation when the “RCC” option is used. The minor allele frequency within each group
does not change. Therefore, the allele chosen as the minor allele is still dependent on the
control group, but a variant can be binned if it is “rare” in either group. Since multiple
variants can be present at a single locus, these rules are applied at each locus using the
most frequent and second most frequent alleles. Once the locus is determined binnable, any
variants at that locus will be considered in the binning analysis. When RCC is OFF at low
binning thresholds, the number of loci in a bin is highly correlated with significance. Using
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the RCC option reduces selection bias and bin size correlation with significance.
Examples E-H in Table 9 show the benefits of using the OMA option. Specifically, when
comparing the low frequency variant count between affected individuals and unaffected
individuals, examples C-D show more similar counts than A-B, but G-H have the exact
variant counts which means that the designation of “control” status is unimportant. Using
rare-case-control and overall-major-allele options require BioBin to review allele counts
collectively between the two groups to choose the minor allele. The individual group minor
allele frequency does not change, but which allele is considered the major (and thus minor)
allele can change. The overall minor allele is not necessarily the control group minor allele.
As shown in examples G-H, this is the ideal condition for a population comparison where
results should be independent of which group is chosen as the control group.
Optional inheritance patterns
BioBin can alter the method of “counting” variants in a bin if the user wishes to employ an
alternative inheritance pattern. The default option utilizes additive encoding, where each
allelic variant adds to an individual bin score. It is also possible to use dominant or recessive
encoding if the user wishes to test a specific hypothesis with those inheritance patterns.
Bin dependency
Bins are often not independent of each other and this should be considered in the statistical
analysis. BioBin provides a measure of dependency in the screen output. Figure 6 shows
a whole-exome analysis example, the total number of binnable variants was 238,145. Of
those, 222,564 variants were binned only once, while 11,255 variants were found in more
than one bin (between 2 and 22 bins). In a gene analysis, only a small proportion of
variants are included in more than one bin (< 5%). One should consider this information
when determining the best method to account for multiple test correction.
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Figure 6. Screen output indicating bin dependency.
Variant weighting
Madsen and Browning were the first to propose using individual variant weights to influence
composite genetic scores. In their original paper, mutations were grouped into a bin and
each individual was scored by a weighted sum of mutation counts. According to Madsen
and Browning, the mutation frequency, qi, for each locus is dependent on the number of
variant alleles observed in unaffected individuals (mUi ) and the number of affected and
unaffected individuals (ni, see Equation 7) The calculated weight (wi) is the estimated
standard deviation of the total number of mutations in the sample under the null hypothesis
(see Equation 8). Finally, the genetic score for each individual is the sum of all variable loci
in the bin divided by their respective weights [55](see Equation 9).
qi =
mUi + 1
2nUi + 2
(7)
wi =
√
ni · qi · (1− qi) (8)
γj =
L∑
i=1
Iij
wi
(9)
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Although the weight sum test is implemented in a nonparametric framework using per-
mutations on sum rank test statistics to estimate significance, it has been noted by us and
others that the calculation of qi based only on the observed control group (unaffected sam-
ples) results in inflated type I error [77]. The original Madsen and Browning implementation
allows bias weighting such that weights in binned alleles with higher frequencies in cases
are unbounded, while weights of alleles with higher frequencies in controls are bounded.
Using this weighting scheme, there is a higher false positive rate even in the presence of no
true genetic effect (see Chapter IV) [77]. To provide an unbiased weight, BioBin permits
a weighting parameter with four options: control weight, overall weight, maximum weight,
and minimum weight. The control weight is reflective of the original Madsen and Brown-
ing calculation, which uses only the number of alleles in unaffected individuals to calculate
qi. The overall weight uses the overall allele count in the calculation of qi and is com-
monly used in popular software association packages [78, 79]. The maximum and minimum
weights are calculated by using the maximum or minimum 1/wi value when qi is calculated
using affected and unaffected individuals. The maximum and minimum weights allow for
weights to reflect large differences in allele frequencies in cases and controls and are more
powerful than using the overall weight option but do not lead to bias in results. Weights
are incorporated similarly to Madsen and Browning to calculate the genetic score for each
individual. Equation 10 shows this relationship and an additional custom weight (wc) that
can be implemented using custom weight input files. Custom weights allow the user to
manage additional weights; for example, one might increase the weight of nonsynonymous
variants to 1.1 to reflect the potential burden of damaging nonsynonymous variation.
γj =
L∑
i=1
Iij · 1
wi
· wc (10)
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Statistical tests
The focus of the BioBin software is to build flexible and biologically relevant bins; therefore,
BioBin does not include any particular statistical test in the software package. The lack
of an implemented statistical test is preferable, since it allows the user the freedom to
choose the most appropriate statistical test given their study data and hypothesis. The
BioBin analyses presented in this thesis use burden tests, a composite genetic score has
been used in multiple statistical frameworks to detect associations between independent
genetic variables and a trait of interest. The following statistical tests were used: logistic
regression, Wilcoxon two-sample rank sum test, and standard permutations. The most basic
genetic score is just the individual’s sum of variants within a single bin. Using weights, each
variant can be influenced by weights based on allele frequency or custom weights provided
by the user. The formula for combining those weights (if present) and calculating a genetic
score is shown in Equation 10.
In the presented analyses, when a logistic regression was used, the null hypothesis of
no effect was tested as β1 = 0. When results were calculated using a Wilcoxon two-sample
rank sum test, a nonparametric method to test if the mean ranks differ between two groups,
the null hypothesis of no difference between the mean ranks was tested. In some analyses,
permutations were used to affirm simulation results. Permutations were performed using
either a Wilcoxon two-sample rank sum test statistic or the rank sum test as described by
Madsen and Browning [55]. For the permutation test, the phenotype was randomly assigned
and the resulting bin was tested 1000 times. The p-value was calculated as the proportion
of permutations in the null distribution that were more extreme than the observed value.
Summary
There are challenges for association detection using binning analyses, variants in the same
bin can have various functional effects (protective, detrimental or neutral), allele frequencies
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at variant positions are often population specific, and there has not been a clear standard for
statistical testing. However, collapsing algorithms improve power in low frequency variant
analyses when large sample sizes ( > 10,000 individuals) are not available. Also, collapsing
methods provide an avenue to embrace allelic heterogeneity, locus heterogeneity, and epista-
sis. Knowledge-based binning increases the likelihood that variants with similar functional
properties will be binned together and that an association signal can be detected. Further-
more, collapsing method results, in particular BioBin results, are interpretable biologically.
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CHAPTER IV
SIMULATION STUDIES
Since low frequency binning is a relatively new approach, BioBin had to be extensively
tested utilizing simulations with multiple statistical approaches and weighting options. Si-
multations described in this chapter were generated using SimRare, a GUI interface for
simuPOP, a forward time simulator [80, 81]. Together, these two software programs sim-
ulate introduction and evolution of rare variants and can allow complex fitness and selec-
tion modeling (http://simupop.sourceforge.net, https://code.google.com/p/simrare/) with
a user-friendly approach. SimRare takes less time and is more computationally efficient be-
cause replicates are generated and data are stored as population averages rather than storing
individual haplotypes. In this study, the term replicate is a realization of the forward-time
simulation using the given input parameters. In each of the studies described in this chap-
ter, 250 replicates were simulated. Each replicate uses the same evolutionary parameters
but differs because of the random seed variables and random genomic size. After the repli-
cate initializations, populations of any size with any genetic effect can be modeled from this
population. In this chapter, the number of times populations are generated from this pool
for testing will be referred to as duplications.
In all of the simulations described below, an additive multilocus model with a selection
coefficient distribution was used, previously described by Kryukov [82]. The mutation
rate was set at of 1.8e−8 per nucleotide per generation. The population sizes were Ne =
8100, 8100, 7900, and 900,000 with 5000 generations, 10 generations, and 370 generations
respectively.
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Type I error assessment
BioBin is a flexible binning algorithm; the variety of available weighting options and variable
size of output bins should be adequately tested in simulated data to provide future users
assurance in their study results. In this chapter, type I error results are presented from
a gene region simulation study, large region simulation study, and two dependent group
simulation studies. The gene region simulation study represents a biological gene region
with a single start and stop position. The large region simulation study represents a much
larger region with a single start and stop position that could be a very large gene, but is
the average size of pathway bins. The first dependent group simulation study represents
pathway bins by randomly selecting gene region simulations into a single bin. The second
dependent group simulation study is similar to the first group simulation, except a single
significant region is forced into each group.
An odds ratio of 1.0 was used for protective and detrimental mutations with an additive
mode of inheritance for 500 cases and 500 controls in each study. Each simulation incorpo-
rated 1% missingness and 1% unphenotyped individuals. The type I error was calculated
as the proportion of simulated duplicates with a p-value ≤ 0.05. An error rate above 5%
would indicate a higher false-positive test and an error rate lower than 5% would indicate
a conservative test.
Continuous region simulation
Type I error was tested using the evolutionary parameters described above to generate
random length simulated regions for two continuous region simulations (each region has
single start and stop position). For continuous region simulations, each duplicate was a
single region of random size and all of the variants from the simulated region were binned
together in a single bin. Each result was tested with all currently available allele frequency
weight options and at least two statistical tests. First, 2000 duplicate regions were simulated
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with random region lengths between 2.5kb and 100kb. Over the 2000 duplicates, the number
of variants in a bin varied between 42 and 4254 (µ = 1813, SD = 1083.17). The size of
bins (number of variants per bin) in this simulation mimicked gene bins created from an
exome study in a natural data set. However, the 2.5kb-100kb duplicates did not create bins
large enough to resemble bins seen in pathway analyses. To address this, the simulation
was extended to create 1012 duplicate larger continuous regions with random region lengths
between 100kb-500kb. The larger regions are very memory intensive to simulate; therefore,
the number of duplicates was less than the number generated for smaller regions. The
number of variants per bin in the larger region study varied from 13,070 to 98,450 (µ =
48690, SD = 19207.4).
The type I error results are shown in Table 10. For each simulation study in the 2.5kb-
100kb continuous region study, five weight options (described further in Chapter III) and
four statistical tests were used. The included statistical tests were: Wilcoxon two-sample
rank sum test, logistic regression, Wilcoxon rank sum test with permutations, and rank
sum test with permutations. For each 100kb-500kb continuous region, five weight options
and two statistical tests were applied: Wilcoxon two-sample rank sum test and logistic
regression.
The weight calculated using the original Madsen and Browning implementation (CTRL)
had a very high type I error in every test except permutation tests. The weights calculated
from overall allele frequency (OVERALL), which is the most common implementation of
the Madsen and Browning test in current online methods, are mostly well controlled, but
increase slightly in analyses with larger bins. Of the novel unbiased weights, the minimum
and maximum weight (MIN and MAX, respectively), the minimum weight had the lowest
type I error and in most analyses was overly conservative.
Using the p-values from each of the type I error simulation results, quantile-quantile
plots were generated to visualize the log p-value distribution (see Figure 7). On each plot,
the size, weight, and statistical test are indicated. The null uniform distribution is shown
in red. Each column represents results from a specific allele frequency weight. For example,
the first column shows all of the results from the CTRL weight analyses. The first two
rows are 2.5kb-100kb analysis results with 2000 replicates. The third and fourth rows are
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Table 10. Type I error simulation results from continuous region simulation studies.
Study Statistical Test Weight Type I error Permutation∗
2.5kb-100kb
Wilcoxon
CTRL 0.5267
OVERALL 0.0525
MAX 0.0715
MIN 0.048
NO WEIGHT 0.0505
Regression
CTRL 0.7856
OVERALL 0.0455
MAX 0.0685
MIN 0.0385
NO WEIGHT 0.043
Wilcoxon
CTRL 0.0535 Y
OVERALL 0.0545 Y
MAX 0.0535 Y
MIN 0.056 Y
NO WEIGHT 0.0505 Y
Sum rank
CTRL 0.0495 Y
OVERALL 0.0485 Y
MAX 0.0475 Y
MIN 0.051 Y
NO WEIGHT 0.0435 Y
100kb-500kb
Wilcoxon
CTRL 0.999
OVERALL 0.0613
MAX 0.0771
MIN 0.0464
NO WEIGHT 0.0563
Regression
CTRL 0.999
OVERALL 0.0514
MAX 0.085
MIN 0.0425
NO WEIGHT 0.0573
∗ N permutations = 1000
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permutation results using 1000 permutations on each of the 2000 replicates from the same
data. The fifth and sixth rows are the type I error results from the 1016 replicates of the
100kb-500kb large region analyses.
The type I error is vastly inflated in every analysis with the exception of the permutation
tests. For comparison, the last column contains the results from BioBin when no weights
are used and the type I error is well controlled.
Pathway simulation studies
From the simulated region tests described above, new knowledge was generated for type I
error under different weight and test conditions; however, the simulations were not quite
comparable to pathway analyses. Variants binned using pathway knowledge are often binned
in multiple pathway bins because genes recur in multiple pathways with high frequency. This
dependency could affect the type I error rate.
To address this, two additional simulation approaches were developed. Between 2-50
bins from the 2000 gene region duplicates were grouped two ways to test type I error. For
both group simulations, five weight options and two statistical tests were applied: Wilcoxon
two-sample rank sum test and logistic regression.
First, between 2 and 50 bins were randomly grouped together (simulating 2-50 genes in
a pathway). Each 2.5kb-100kb bin could only appear once in a group simulation bin, but
could appear multiple times across the 1000 group simulations. Second, this was repeated
and the most significant bin (p-value ∼ 1e−04) from the null 2.5kb-100kb bin analysis was
forced into each group. One thousand new groups were created by randomly combining
between 2 and 50 bins including the forced the false positive bin into each group. The
type I error was measured as the proportion of total replicates with a p-value of less than
or equal to 0.05. In the second group analysis, since a known signal was forced into each
bin, the reported error was not truly type I error. However, it was important to consider
how a single bin or region of signal can be propagated to larger bins and how the signal is
balanced by noise.
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Table 11 shows the type I error results from the group simulations. Quantile-quantile
plots are shown in Figure 8. The top two rows show the p-value distribution from 1000
duplicates of the first group simulation which contained between 2-50 random bins from the
2.5kb-100kb region analyses. The last two rows show the p-value distribution from the 1000
duplicates of the group simulations which contained between 2-50 bins from the 2.5kb-100kb
region analyses with the forced false positive bin in each group. As shown in Table 11 and
Figure 8, the control weight does not manage type I error under any simulated conditions
without permutation. In the completely random group simulation study, the other four
weights manage type I error reasonably well. Maximum weight is slightly anti-conservative
while the other three are conservative. In the random group with a forced signal, the type
I error is always anti-conservative because the bins are not designed for a true type I error
assessment. Of the four weights, minimum weight and no weight are the most conservative.
Correlation between significance and bin size
Shown in Table 10 and Table 11, the type I error regardless of weight increases in the three
large bin simulation studies (100kb-500kb and two group simulations). The analyses using
the MIN weight or no weight were the least affected, but type I error did still increase. It
is important to understand if the increase in type I error was completely explained by the
size of the bin or if the increase in type I error was compounded by bin dependency (bins
are present in more than one group, which is common in pathway analyses). In each of the
simulation studies, the correlation between each bin p-value and the number of variants in
that bin was evaluated.
In Figure 9, each plot shows the fitted linear correlation line between bin p-values and
the number of variants in that bin. The colors represent the five weight conditions used
in the simulation testing. There is also a black line at y = 0.5 to represent the null
correlation between p-value and number of variants in a bin. In each simulation study, the
CTRL weight is highly affected by the number of variants in a bin because of the selection
bias described in a later section. This effect is most evident in the three large simulation
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studies, note the type I error for the large region simulation study and the two group
simulation studies was over 99% (see Table 10 and Table 11). The Spearman correlation
was tested in each of the four simulations with minimum variant weights applied using the
regression p-value and size of bin. The top left plot shows the results from the 2.5kb-100kb
continuous region analysis. The number of variants in a bin varied between 42 and 4254
(µ = 1813, SD = 1083.17, Spearman correlation ρMIN = −0.0258, p− valueMIN = 0.102).
Weights other than the CTRL weight have only a marginal decrease in p-values at the
high end of gene region simulation study. The MIN weight does not appear to decrease at
all, but stays with the null line at y = 0.5. The top right plot shows the results from the
100kb-500kb large continuous region simulation study, the number of variants per bin varied
from between 13,070 to 98,450 (µ = 48690, SD = 19207.4, Spearman correlation ρMIN =
0.00729, p − valueMIN = 0.743). The non-CTRL weights do not show a strong trend
between p-value and the number of variants in a bin. The bottom left plot shows the
results from the group simulation study, the number of variants per bin varied between 922
variants to 106,300 variants (µ = 47670, SD = 26325.97, Spearman correlation ρMIN =
−0.0203, p − valueMIN = 0.365). Without regard to the CTRL weight, each of the other
weight conditions show a minor decreasing trend, indicating that larger group bins contain
dependencies with slightly lower p-values. The bottom right plot shows the results from
the 2.5kb-100kb group simulation study, where the most significant null bin was forced into
each group. The number of variants per bin varied from 3330 to 115,000 variants (µ =
48400, SD = 27206.31, Spearman correlation ρMIN = 0.287, p − valueMIN = 3.9e−39).
There is a noticeable correlation between p-value and bin size. As the bin size increases,
the signal from the single false positive bin is mitigated.
Non-bias variant weighting comparison
The simulation results indicate that relying on the variant weights based entirely on controls
drastically increases the type I error in all statistical tests except permutation testing. Even
worse, this bias is magnified with the size of the bin, introducing a spurious correlation that
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can confound results. By weighting solely on the control population, the user introduces
a bias similar to the bias described by Lemire [77]. Three options for weighting were
implemented that eliminate selection bias. The most common method is to weight loci by
their overall frequency in the case and control population combined. While this reduces
type I error, it also reduces statistical power. In a recent population comparison of low
frequency variants, many loci that were nearly fixed in opposite directions were found. If
one used the overall weight, these loci would be extremely down-weighted, even though they
are incredibly relevant [83].
The other two unbiased methods use either the minimum or the maximum of the weights
calculated for each population individually (e.g. min( 1
wUi
, 1
wAi
) or max( 1
wUi
, 1
wAi
). In simu-
lation tests, the minimum weight better controlled the type I error and in most cases was
overly conservative. Figure 10 shows the Madsen and Browning estimate of variance (wi)
and the respective locus weight for large populations and varying allele frequencies. As can
be seen in Figure 10, when using the locus maximum weight with a minor allele frequency
cutoff (vertical line), the locus weights are constrained within a limited range; however,
there is no such constraint when using the minimum weighting option.
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Power simulation assessment
Varying sample size
In addition to the parameters described in the Simrare section, to evaluate power, a sample
data set was generated with the following parameters: fixed 5kb simulated region, 0.9 odds
ratio for protective mutations, 2.5 odds ratio for detrimental mutations, and an additive
mode of inheritance. A protective odds ratio was 0.9 to add noise to the data. The
detrimental odds ratio was designated as 2.5 to provide a conservative estimate of power.
Most literature reviews expect causative low frequency alleles to have odds ratios ≥ 2 [2].
Four sample sizes were created: 2000, 1000, 500, 250. Case/control status was evenly and
randomly assigned in each of the 4000 duplicates. Missingness or unphenotyped individuals
were not incorporated. The power was computed as the percentage of the 4,000 duplicates
with a p-value ≤ 0.05. As shown in Table 12, the power is greater than 90% at sample sizes
of 1000 and 2000 individuals. The power drops to 75% at a sample size of 500 and 50% at
a sample size of 250. While the power drops dramatically with decreasing sample size, it is
important to note that power to detect associations relies heavily on the effect size of the
variants.
Table 12. Power analysis using fixed 5kb simulations with 4000 replicates for each of four sample
sizes (N=2000, 1000, 500, and 250). Note: for each sample size, the number reflects the total number
of individuals (i.e. N=2000 translates to 1000 cases and 1000 controls).
Sample Size Power
2000 0.9910
1000 0.9340
500 0.7575
250 0.5030
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Unequal sample size and comparison with other methods
The last test was designed to generate a sample data set evaluating power similar to the
cystic fibrosis study sample (see Chapter VI), the following parameters were used: randomly
generated bins ranging from 1kb to 10kb; 0.9 odds ratio for protective mutations; 2.5 odds
ratio for detrimental mutations; and an additive mode of inheritance for 100 cases and
300 controls under three scenarios: 100% functional variants, 50% functional variants, and
25% functional variants. In this case, missingness or unphenotyped individuals were not
incorporated. The power was calculated as the proportion of the 1,000 duplicates with a
p-value ≤ 0.05.
The power of BioBin using multiple weight conditions in a logistic regression and
Wilcoxon two-sample rank sum test framework was compared with other published meth-
ods: combined multivariate and collapsing method (CMC), Kernel-based adaptive cluster
test (KBAC), rare variant threshold test (MZ), weighted sum statistic (WSS) and variable
threshold test (VT) [81]. The power analysis results are shown in Figure 11, Figure 12,
and Figure 13. The corresponding type I error for each method is shown in text on each
graph. The most powerful BioBin result uses CTRL weight, which has a tremendous type
I error rate (red line). The most powerful BioBin weight with controlled type I error is the
minimum weight using a logistic regression test; it is second only to the variable threshold
method first described by Price et al. [56].
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Figure 11. Power estimates for multiple binning strategies on simulated data with 100 cases and 300
controls where only 25% of variants are functional. For reference, the corresponding Type I error
values are provided for each test.
62
Figure 12. Power estimates for multiple binning strategies on simulated data with 100 cases and 300
controls where only 50% of variants are functional. For reference, the corresponding Type I error
values are provided for each test.
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Figure 13. Power estimates for multiple binning strategies on simulated data with 100 cases and
300 controls where 100% of variants are functional. For reference, the corresponding Type I error
values are provided for each test.
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Summary
The power and type I error estimates are dependent on sample size, effect size, and BioBin
parameters. Minimum variant weighting was the most powerful and most conservative
weighting framework. Permutations were used for some of the calculations provided but
were not necessary to maintain reasonable type I error rates as long as the variant weights
were unbiased. Lastly, bin size does not appear to increase type I error. Dependency
within bins (such as found in pathway analyses) can minimally increase the type I error.
Additionally, a child bin or variant with a strong signal can propagate signal through larger
parent bins in a size dependent manner. Overall, the bins provided by BioBin are most
powerful if the total sample size is greater than 500 individuals and minimum weighting is
used.
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CHAPTER V
1000 GENOMES PROJECT DATA: POPULATION COMPARISON OF
LOW FREQUENCY BURDEN
Low frequency variants are likely to play an important role in uncovering complex trait
heritability; however, they are often population specific or unique to populations within a
continent. This specificity complicates genetic analyses investigating low frequency variants
for two reasons: low frequency variant signals in an association test are often difficult to
generalize beyond a single population or continental group and there is an increase in false
positive results in association analyses due to underlying population stratification. In order
to reveal the magnitude of low frequency population stratification, pairwise population
comparisons were performed using the 1000 Genomes Project Phase I data to investigate
differences in low frequency variant burden across multiple biological features.
Methods and results
Binning approach
NCBI dbSNP and NCBI Entrez Gene were chosen as the primary sources of position and
regional information [61]. Pathway/group bins, regulatory regions, and evolutionary con-
served regions were created using sources available in LOKI (sources detailed in Chapter III).
Some sources explicitly provide lists of genes in pathways, others provide groups of genes
which share a biological connection (e.g. protein-protein interactions). For the purposes of
this study, any bin created by multiple regions/genes was analyzed in the Pathway-Groups
feature analysis. External custom input files were generated using boundaries of annotated
exon regions from UCSC to bin exon and intron specific variants. For example, if Gene A
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Table 13. Excerpt of custom region file containing regions with signatures of natural selection
Chr ID Start(bp) Stop(bp)
1 CMS EUR:reg1 1490074 1509034
1 CMS ASN:reg2 16414784 16417992
1 CMS AFR:reg3 26917014 26936774
1 CMS EUR:reg4 30707291 30724056
has three exons and two introns, only two bins would be created: GeneA-exons and GeneA-
introns. GeneA-exons would contain all variants that fell within any of the three Gene
A exon boundaries. External custom feature files were also generated for regions under
natural selection by combining regions provided by previously published work [84, 85]. An
excerpt of the custom region natural selection file is shown in Table 13.
Statistical analysis
BioBin is a bioinformatics tool used to create new feature sets that can then be analyzed in
subsequent statistical analyses. Statistical tests used with BioBin can be chosen according to
the hypothesis being tested, the question of interest, or the type of data being tested. Unless
otherwise noted, the results presented here were calculated using a Wilcoxon 2-sample rank
sum test implemented and graphed in the R statistical package [86, 87]. P-values presented
have been corrected using a standard Bonferroni correction, adjusting for the number of
bins created and tested in a given analysis.
1000 Genomes Project data
To investigate low frequency variant population stratification using BioBin, 1000 Genomes
Project Phase I data were analyzed. The 1000 Genomes Project was started in 2008 with the
mission to provide deep characterization of variation in the human genome. As of October
2011, the sequencing project included whole-genome sequence data for 1094 individuals,
and aimed to sequence 2,500 individuals by its completion [88]. Table 14 provides the total
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number of variants (common and low frequency) and individuals included in Phase I VCF
files of 1000 Genomes Project data for 1094 individuals in all 14 populations. Cryptically
related individuals (N=75) were removed and a pairwise comparison of low frequency variant
burden differences between 14 populations was conducted.
In addition to the differences in overall magnitude of variation between these population
groups, there were also differences in the distribution of this variation. In Figure 14, the al-
lele frequency density distribution plot of chromosome 1 for all 14 populations is presented.
On chromosome 1, African descent populations have the highest density of low frequency
variation. Others have found a similar trend genome-wide [60]. In general, the African
ancestral populations not only have more variants overall than other ancestral groups (see
Table 14), these populations also have a higher distribution of low frequency variants than
other ancestral groups (see Figure 14). Although the number of individuals in a given popu-
lation affects the identification of low frequency variants, the trends seen in Figure 14 reflect
ancestry, not population size. The cyclic blue line corresponds to the Iberian population,
which only contains 14 individuals. The smaller sample size is responsible for discrete allele
frequency values and irregular allele frequency distribution.
Although low coverage next generation sequence data are prone to errors, no evidence
exists to support the theory that sequence technology led to differential bias in a way
that could explain the trends found in this chapter. In a recent publication by the 1000
Genomes Project, the authors declared sequence errors to be relevant to the technology
used but not to have any correlation with population identity. In order to determine if there
was differential bias across populations or continental groups based on sequence technology,
principal component analyses in each continental group were performed and global variation
differences in the context of sequence technology were reviewed (similar approach to recent
1000 Genomes Consortium paper). Sequence technologies used for each population in the
Phase I release (see Table 15) [60] were examined. Before removing the 75 cryptically
related individuals, only the TSI population was sequenced on a single technology. However,
after dropping cryptically related individuals, CHB, CHS, and JPT were also sequenced
exclusively with Illumina technology.
In Figure 15, the first two principal components calculated from each of the four conti-
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Figure 14. Minor allele frequency distribution on chromosome 1 for 14 1000 Genomes Project Phase
I populations. Groups are color coordinated by continental ancestry: greens=African descent (YRI,
LWK, ASW); blues=Mexican/Spanish descent (IBS, PUR, CLM, MXL); orange/reds=European
descent (GBR, FIN, CEU, TSI); and pink/purple colors=Asian descent (JPT, CHB, CHS). The
populations of African descent have the highest proportion of low frequency variation. The cyclic
blue line is the IBS (Iberian) population, which only contains 14 individuals. This reduces the overall
available spectrum of variant frequency; IBS are thus an outlier in many of the presented analyses.
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nental groups shown in Table 15 are plotted. The scatter plots are colored using population
identity and then sequence technology. From Figure 15, it is clear that within continental
groups, the largest source of variation is sequence technology. In all four groups, the first
principal component perfectly separates based on technology. However, the variation does
not also coincide with population identity and there is overlap between populations since
few populations were sequenced on a single technology. This reduces the likelihood that
sequence technology causes differential bias in the resulting trends of the presented analyses
(see Table 15 and Figure 15).
Investigation of allele sharing
In any genetic study, and especially in consideration of low frequency variants, it is im-
portant to evaluate sample relatedness and allele sharing. To accomplish this, identity-by-
descent (IBD) was investigated in very common variants (MAF > 5%), to assess relatedness.
Second, a more traditional method of assessing cryptic relatedness was used, LD pruned
variants with MAF > 5% in continental groups were used to parsimoniously eliminate cryp-
tically related individuals. Third, identity-by-state (IBS) within populations was assessed
with and without cryptically related individuals. Lastly, IBS was calculated within conti-
nental groups in low frequency variants (MAF < 5%) and very common variants (MAF >
25%).
Population groups were combined into continental populations (i.e. AFR continen-
tal group included ASW, LWK, YRI) and sample relatedness was evaluated between and
within the general ancestry groups using identity-by-state (IBS) and identity-by-descent
(IBD). Pairwise IBS represents the number of shared alleles at a specific locus between two
individuals. IBS can be observed as 0, 1, or 2 depending on how many alleles are in common
between the pair. If the shared alleles are inherited from a recent common ancestor, they
are also considered IBD. Pairwise IBS calculations for low-frequency variants approximate
IBD since the variants are likely to be recent and the chance of being identical because of re-
currence is rare [89]. PLINK and PLINK-SEQ were used to estimate pairwise IBS and IBD
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for individuals of the same general ancestry group (http://atgu.mgh.harvard.edu/plinkseq/,
http://pngu.mgh.harvard.edu/ purcell/plink/) [78]. In each analysis, evidence of increased
relatedness was found in ASW (African ancestry, USA), CHB (Han Chinese Beijing, China),
CHS (Han Chinese Shanghai, China), CLM (Medellin, Columbia), GBR (England and
Scotland), JPT (Japan), LWK (Luhya, Kenya), and MXL (Mexican Ancestry, California)
populations.
Identity by descent (IBD) in all 1094 individuals
In most genomic studies, subject relatedness is calculated using common variants. There-
fore, in the first allele sharing analysis, IBD was estimated using only common variants
(MAF > 10%) in all 1094 individuals available in the Phase I release. In Figure 16, the
y-axis and x-axis correspond to the proportion of markers identical by descent between a
pair of individuals sharing one allele versus none. Small clusters of individuals in the top
left quadrant correspond to more allele sharing than expected from unrelated individuals.
For example, the green points in the left plot of Figure 16A represent a subset of approx-
imately 10 related individuals in the LWK population. Each point represents the IBD
estimate between two LWK individuals. The pairs that share one allele at almost 100% of
possible loci (Z1∼1) and share at least one allele at all loci (Z0∼0) represent a parent-child
relationship. Siblings cluster near the center of the plot while pairwise IBD estimates for
completely unrelated individuals cluster in the lower right quadrant. In Figure 16, there are
several within-population plots that show increased allele sharing within population groups
(A,C,E,G). However, there does not appear to be any increased sharing between population
groups (B,D,F,H). For example, even though there are individuals in the LWK population
that appear to be related (see Figure 16A), none of the three African descent populations
appear to have closely related individuals across populations (i.e. LWK-YRI are not related,
Figure 16B).
In Figure 16, the pairwise calculations with a proportion of IBD greater than 0.5 were
composed of 16 LWK individuals, each with evidence of first and second-degree relation-
ships within the LWK population. Two of the four top related IBD pairwise compar-
isons in LWK have been calculated in other studies as parent-child relationships [90].
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Most of the apparent relationships in the IBD plots above have been identified previously
and are available on the 1000 Genomes Project website [http://www.1000genomes.org/
phase1-analysis-results-directory, cryptic relation analysis].
Evaluating cryptic relatedness
For common variants, an independent subset of SNPs with a minor allele frequency greater
than 5% and r2 linkage disequilibrium values less than 0.2 was created to calculate pairwise
IBD between individuals. For example, the populations of African descent (LWK, ASW,
and YRI) were grouped, and the IBD calculated using all of the individuals from these
three populations. Maximally connected or related individuals were removed in a parsimo-
nious and iterative manner and the IBD analysis was repeated until the maximum pairwise
pi hat score was less than or equal to 0.3. After repeating this analysis in each continental
group, 75 individuals were dropped from BioBin analyses based on the threshold for cryptic
relatedness. The remaining 1,019 individuals were used for the binning analyses presented
in this paper.
Within population identity by sharing (IBS)
An alternate allele sharing method described by Abecasis et al. uses IBS rather than IBD to
review allele sharing [91, 92]. In the case of low frequency or rare variants, IBS approximates
IBD. Figure 17 shows within population IBS for all 14 populations for variants with a MAF
< 3%, where each point represents a pairwise IBS calculation within the same population
(i.e. IBS calculation between YRI-YRI individuals but not YRI-CEU individuals). In
Figure 17A, the pairs with average IBS calculations that fall outside of the cluster are
cryptically related individuals with increased allele sharing. Figure 17B shows the IBS
calculations after removing 75 individuals with cryptic relatedness.
Within continental group, IBS calculations in low frequency and common variants
Allele sharing was evaluated between major ancestral groups using PLINK-SEQ to calculate
IBS for low frequency variants and common variants (threshold MAF < 3% and MAF
> 25%, respectively). Using the ratio of shared alleles divided by the total number of
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Figure 17. Within population identity-by-state (IBS) estimations A) before and B) after removing
individuals with cryptic relatedness. The x-axis represents the IBS mean for low frequency variants
averaged over 22 autosomal chromosomes. The y-axis corresponds to the standard deviation of IBS
scores across 22 autosomal chromosomes. The colors and point types correspond to each population;
color schemes correspond to general ancestry groups as defined for Figure 14. Each point represents
a population pairwise IBS calculation (i.e. YRI-YRI, not YRI-CEU). Identifying and excluding
related individuals removes the outliers seen in the top plot.
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genotyped alleles between two individuals, excess sharing of low frequency variants was
compared to excess sharing of common variants. Again, there was increased sharing among
ASW, CHB, CHS, CLM, GBR, JPT, LWK, and MXL populations before removing the 75
cryptically related individuals.
Figure 18 shows the mean IBS calculations (averaged across 22 autosomal chromosomes)
in low frequency variants for all pairwise individuals within a continental ancestry group.
The left plot (Figure 18A) corresponds to the IBS calculations for all 1094 individuals;
the right plot (Figure 18B) shows the IBS calculations after removing cryptically related
individuals. The x-axis corresponds to the index number comparison; each x index value
represents one pairwise comparison. The comparisons are grouped and colored by type (i.e.
CHS-CHS and CHS-JPT). The y-axis corresponds to the mean IBS calculation across all
22 autosomal chromosomes. In Figure 18, low IBS means correspond to very little allele
sharing for variants with MAF < 0.03. Higher IBS means correspond to more allele sharing
(and perhaps relatedness) among individuals in that pair. For example, there is increased
sharing of alleles with < 3% MAF among LWK pairs (teal peaks, Figure 18A).
Common variant IBS calculations alone overestimate IBD; however, the analysis was
repeated for common variants, results are shown in Figure 19. For common variants, the
IBS calculations were measured using only variants with a continental group minor allele
frequency of 25% or higher. In Figure 19, the left plot shows the IBS calculations in all
1094 individuals; the right plot shows the IBS calculations after removing 75 cryptically
related individuals. The same peaks of increased sharing in LWK, ASW, GBR, CHS, and
MXL are seen and the removal of those cryptically related individuals reduces the amount
of sharing in those populations.
Genomic feature exploration
After determining which individuals to exclude from this study, the feature options of BioBin
were used to investigate a variety of biologically relevant bins for differences in low frequency
variant burden across 14 populations. Feature selection in BioBin is a clear innovation over
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other available collapsing methods. Knowledge of biological features, such as genes and
pathways, are available through LOKI for binning. The minimum bin size was set to two
variants, the interregion bin size was chosen to be 50kb, and a MAF binning threshold of
0.03 was implemented. A 3% MAF binning threshold was chosen to focus the analysis on
rare and near rare variation that differs between population groups. Genes (introns, exons,
nonsynonymous variants, and predicted deleterious variants), intergenic regions, pathways,
pathway-exons, regulatory regions, evolutionary conserved regions, and regions thought to
be under natural selection were binned.
Results are shown in Figure 20, Figure 21, Figure 22, Figure 23, Figure 24, and Figure 25.
Each matrix plot indicates the proportion of significant bins (after Bonferroni correction)
out of the total number of bins generated between two populations. The color intensity
represents the proportion of total bins that were significant [0, 1]. Overall, there are large
differences across populations with regard to low frequency variant burden, and the dis-
tribution of low frequency variants is not random across the genome. The magnitude of
stratification corresponds to the mutational landscape of the region. Note: although Iberian
(IBS) populations are often clustered with European groups, and it makes sense to do so,
a hierarchical clustering algorithm grouped the small population with Spanish/Mexican
populations in the matrix plot results.
Coding and noncoding regions
NCBI Entrez database was chosen to provide the boundaries for gene regions and created
a custom role file of intron and exon boundaries using data provided from UCSC Genome
Browser [71]. In Figure 20, the top matrix corresponds to bins created using gene exon
boundaries, the middle matrix corresponds to bins created using gene intron boundaries,
and the bottom matrix corresponds to bins created using regions between genes (intergenic).
The abbreviations for the each population are found on the x and y-axes. The numbers
in each block and the color intensity [0, 1] indicate the proportion of significant bins (after
Bonferroni correction) for the 1000 Genomes populations on each axis, where the darker
the color, the higher the proportion of significant bins. In general, the x-axis is organized
with African descent populations on the far right and increasing differentiation with regard
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to low frequency burden towards the left (i.e. populations of Asian descent have the highest
proportion of significant bins compared to African descent groups).
The coding regions show a trend of a lower proportion of significant bins with low fre-
quency variant burden differences than either the intron or intergenic bins. For example,
in the CEU (Northern/Western European Ancestry, USA), YRI (Yoruba African) compar-
ison, approximately 44% of the gene exon bins had significant differences in low frequency
variant burden. In contrast, the noncoding region bins, gene-introns and intergenic bins
had 66% and 70% of bins with significant differences in low frequency variant burden. The
coding regions appear to be under more constraint across populations than noncoding re-
gions. Comparing only the noncoding regions, introns tend to have slightly fewer variation
differences than intergenic bins, most likely because introns are by default nearest neighbors
to the selective pressures on coding regions.
The gene exon bins were filtered using annotations from the Variant Effect Predictor
Software (VEP) [75]. Gene bins were created with only nonsynonymous variants and a
second analysis using only predicted damaging variants annotated by SIFT or PolyPhen-
2 [72, 74, 75]. The results in Figure 21 indicate that these potentially functional and
significant changes are even more conserved between populations than coding regions (Fig-
ure 20A).
ORegAnno annotated regions
The database ORegAnno (Open Regulatory Annotation database) was used to define reg-
ulatory region boundaries for the bin analysis. The top matrix of Figure 22 shows the 91
population comparisons for the ORegAnno regulatory feature analysis.
In comparison to Figure 20, the annotated regulatory regions have fewer significant bins.
For example, in gene exon analysis shown in Figure 20, approximately 44% of the ASW-
CHB gene-exon bins contained significant differences in low frequency burden. However,
in Figure 22, only 28% of the ASW-CHB annotated regulatory bins contained significant
differences in low frequency burden. This trend is consistent across the matrix of population
comparisons; regulatory regions have fewer significant bins than the coding or noncoding
features of the same population comparison.
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Figure 20. Proportion of significantly different bins in A) gene exon, B) gene intron, and C) intergenic
regions. The proportion of significant bins across all population comparisons increases from coding
(A) to noncoding (B) and finally intergenic (C) regions.
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Figure 21. Proportion of significantly different bins for gene exon filters: A) nonsynonymous and
B) predicted deleterious variants. The abbreviations for the each population on are on the x and
y-axes. The numbers in each block and the color intensity [0, 1] indicate the proportion of signif-
icant bins (after Bonferroni correction) for the 1000 Genomes populations on each axis, where the
darker the color, the higher the proportion of significant bins. In general, the x-axis is organized
with African descent populations on the far right and increasing differentiation with regard to low
frequency burden towards the left (i.e. populations of Asian descent have the highest proportion of
significant bins compared to African descent groups). Filtering gene exon regions by mutation type
and predicted functional significance lead to smaller bins and overall greatly reduced proportions of
significance.
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Figure 22. Proportion of significantly different bins in A) ORegAnno regulatory and B) pathway
feature analysis. The abbreviations for the each population on are on the x and y-axes. The
numbers in each block and the color intensity [0, 1] indicate the proportion of significant bins (after
Bonferroni correction) for the 1000 Genomes populations on each axis, where the darker the color,
the higher the proportion of significant bins. In general, the x-axis is organized with African descent
populations on the far right and increasing differentiation with regard to low frequency burden
towards the left (i.e. populations of Asian descent have the highest proportion of significant bins
compared to African descent groups). From more conserved regulatory regions to relatively large
binned pathways, Figure 22A shows conservation in comparison to genic regions (Figure 20) and
Figure 22B shows occasionally very high proportions of significant bins in parent pathway bins in
comparison to genic regions (Figure 20).
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Pathway and group features
Several biological pathway and group sources from LOKI (the Library of Knowledge Inte-
gration, described in detail in Chapter III) were used to generate low frequency variant bins:
PFAM, KEGG, NetPath, PharmGKB, MINT, GO, dbSNP, Entrez, and Reactome. The
Figure 22B shows the 91 population comparisons for the pathway group feature analysis.
Of all of the feature analyses, pathway bins consistently show the highest proportion
of significant differences in low frequency variant burden between populations. There are
several potential explanations. First, since pathway bins are generally much larger than the
other feature types, it is possible that large bins increase the false positive rate. Second,
the same genes and regions can recur in multiple pathways. If the region has significant
differences in low frequency variant burden, then each pathway or group containing that
region will have a higher chance of having significant differences in low frequency variant
burden. Following this logic, a pathway containing many genes has a higher chance of
having at least one gene with extreme low frequency variant stratification. To compare
only coding regions within a pathway, the pathway analysis was filtered to include only
variants within exons. The proportions are reduced (shown in Figure 23) but still higher
than the gene exon proportions shown in Figure 20A.
Evolutionary conserved regions (ECRs)
PhastCons output downloaded from UCSC Genome Browser was used to derive evolutionary
conserved feature boundaries for primates, mammals, and more than 40 species of verte-
brates. Figure 24 shows the 91 population comparisons for the ECR feature analysis. The
numbers in each block and the color density indicate the proportion of significant bins for
the 1000 Genomes populations on each axis. For example, in the ECR: vertebrate matrix,
16.38% of the ECR bins have significant differences in low frequency burden between YRI
and CHS populations. In general, the x-axis is organized with African descent populations
on the far right and increasing differentiation with regard to low frequency burden towards
the left (i.e. populations of Asian descent have the highest proportion of significant bins
compared to African descent groups). Of all of the feature analyses, ECR bins had the
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Figure 23. Proportion of significantly different bins for the pathway-exon feature analysis. The
numbers in each block and the color intensity [0, 1] indicate the proportion of significant bins for
the 1000 Genomes populations on each axis. In general, the x-axis is organized with African descent
populations on the far right and increasing differentiation with regard to low frequency burden
towards the left (i.e. populations of Asian descent have the highest proportion of significant bins
compared to African descent groups). The overall proportion of significant bins is much less in this
pathway-exon analysis than the pathway analysis shown in Figure 22B.
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smallest proportion of significant bins. More ancestrally similar populations tended to have
negligibly low frequency burden differences in these conserved segments. For example, ap-
proximately 7% of the ECR region bins (vertebrate alignment) were significantly different
between FIN (Finnish) and JPT (Japanese) individuals. However, the significant number
of bins between the two ancestrally similar GBR (British) and CEU individuals was less
than 1%.
Regions of natural selection
Natural selection can alter genomic variation in features, particularly in regions with some
impact on protein function (regulatory regions, coding regions). Positive selection on a
specific variant allows the advantageous variant to sweep through a population, which can
lead to an excess of common variants. Alternatively, weak negative selection or purifying
selection can result in selective removal of deleterious alleles. This can decrease variation
around the locus under selection and lead to an excess of rare or low frequency variation [93].
Commonly, evidence of natural selection is found only in one ancestral group, which is
consistent with the idea that these selection events postdate population separation [94].
Because of this differentiation among populations, regions identified as being under selective
pressures were used as features in a BioBin analysis. Table 16 shows the analysis plan,
features tested, sources used, and the mean number of bins generated across all pairwise
comparisons.
To investigate regions of natural selection, a feature list was created using regions re-
cently identified/confirmed by Grossman et al. with the Composite Multiple Signals algo-
rithm on the 1000 Genomes Project data [84]. In addition, a publication by Barreiro et al.
provided a list of specific genes with the strongest signatures of positive selection; i.e. genes
that contained at least one nonsynonymous or 5’ UTR mutation with an FST value greater
than 0.65 [85].
After lifting positions to human genome build 37, there were only 368 remaining re-
gions from the original regions identified by Grossman et al. The results are shown in
Figure 25. The top plot corresponds to regions identified in African ancestry, the middle
plot corresponds to regions identified in populations of Asian ancestry, and the bottom
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Figure 24. Proportion of significantly different bins in evolutionary conserved region feature analysis
A) conserved with primates, B) conserved with mammals, and C) conserved with vertebrates.
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Table 16. Analyses performed for each population comparison: features tested, contributing sources,
and total of bins generated for each analysis.
Analysis Feature Source AVG Bin Total
A
Genes-Exons(NS/DEL) NCBI Entrez, UCSC roles
80786
Genes-Introns NCBI Entrez, UCSC roles
Genes-Unknown NCBI Entrez, UCSC roles
Intergenic (50kb) -
B Pathway/Groups
PFAM, KEGG, NetPath,
PharmGKB, MINT, GO,
dbSNP, Entrez, Reactome
178497
C Natural Selection
Pritchard/Stoneking
Grossman
?
368
D ORegAnno UCSC-ORegAnno 11293
E
ECR-vertebrates
ECR-placental mammals
ECR-primates
UCSC-PhaseCons 319269
plot corresponds to regions identified specifically in populations of European ancestry. The
trends in these three matrix plots are distinctly different from the trends shown in Fig-
ures 20, Figure 21, and Figure 22. The blocks of comparisons within a continental group
(shown in black boxes on each matrix plot) still have very little color, indicating that the
low frequency variant burden between populations within a continental group is very sim-
ilar. The main difference is the gain of intensity outside of the continental groups. For
example, in Figure 25B (regions identified in Asian populations), the European continental
group and Spanish continental group are most likely to have proportions over 60% when
compared to populations of Asian descent. In the same plot, the populations in the African
group have proportions over 85% when compared to populations in the Asian group.
In general, regions considered to be under natural selection were unlikely to have sig-
nificant differences in low frequency burden between ancestrally similar populations, and
very likely to have significant differences in regions considered to be under natural selection
between ancestrally distant populations (see Figure 25).
Regions of natural selection have been identified using various methods often in a popu-
lation specific manner. Therefore, large differences were expected in low frequency variant
burden between populations that have not shared similar evolutionary history. Specific
genes provided by Barreiro et al. that have been found to show the strongest signatures of
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Figure 25. Proportion of significantly different bins in natural selection analysis by region of iden-
tification: A) AFR continental group, B) ASN continental group, and C) EUR continental group.
The regions of natural selection, particularly negative selection, are often accompanied by excess low
frequency variants. As world populations evolved, selective forces were often unique and location
specific. Therefore, the evolution of low frequency variants compared across world populations can
be markers of past selective events. Populations within a continental group are very similar and
there are high proportions of statistically significant bins between populations of different continental
groups.
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positive selection were investigated. These genes contain at least one nonsynonymous or 5’
UTR mutation with an FST value greater than 0.65 [85].
Using CEU/CHB/YRI populations as representative populations from the European,
Asian, and African ancestral groups, the regions of natural selection associated with the
gene list provided by Barreiro with overlap in one of two other publications are shown in
Table 17 and Table 18 [84, 95, 96]. This table includes the number of loci in the bin, total
binned variants from both populations, and the bin p-value. The source author corresponds
to the paper for that particular region. The “relevant population” describes the population
where the signature of selection was found.
Next, particular genes known to have allele frequency differences between populations
were of interest, including Lactase, Phenylalanine Hydroxylase, CTCF, and CFTR. Table 19
shows the BioBin p-value results for three representative populations (YRI, CEU, CHB)
in each gene bin. For example, the Lactase gene had a significant low frequency variant
burden difference between CEU/CHB and CEU/YRI but not YRI/CHB. On the other
hand, CFTR was significantly different between CEU/CHB, CEU/YRI, and YRI/CHB.
Linkage disequilibrium in binned low frequency variants
Although low frequency variants are commonly assumed as independent (in low linkage dis-
equilibrium (LD) with other variants), there are rare haplotypes within related individuals
and populations [97]. Linkage disequilibrium (LD) was investigated in 10 top-ranked bins
for three population comparisons, CEU-CHB, CHB-YRI, CEU-YRI. LD was calculated be-
tween binned variants and the number of variants inside of a bin in LD with an r2 > 0.3
was calculated.
In Figure 26, three pairwise population comparisons are shown. The top 10 ranked bins
were investigated from the CEU-CHB (A), CHB-YRI (B), and CEU-YRI (C) coding and
noncoding analyses for presence of LD (r2 > 0.3) between two variants in the same bin. The
abundance of white space illustrates the lack of rare haplotypes in the top most significant
bins.
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Figure 26. Proportion of loci in top bins in high LD with other variants in the same bin. Each bar
represents a gene or intergenic bin. For a particular population comparison, the total height of the
bar corresponds to the number of loci in that bin. The shades of blue and purple correspond to loci
with r2 LD values greater than 0.3 for a specific population shown in the legend. The variant can be
in LD in one population, the other population, or both (described in each legend). Almost all of the
low frequency loci in LD had r2 values of approximately 0.5 or 1, corresponding to almost perfect
LD. The white space corresponds to loci in the bin with LD values less than 0.3. The top bins are
therefore, mostly composed of independent loci.
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Pathway correlation with bin size
Since the proportion of significant bins in the feature analyses is considerably higher for
pathway bins than any other feature, the correlation between pathway p-value and bin size
was of particular interest. The pathway feature for the CEU-YRI population comparison
was chosen to assess the correlation between significance and several characteristics of the
pathways. All of the pathways in the YRI/CEU analysis were compiled, and the following
information for each pathway bin was obtained: total genomic coverage, number of genes,
number of independent genes, number of loci, number of variants, and BioBin p-value.
Because the majority of pathways or groups were not very large, the data was heavily
skewed (see Figure 27). A log10 transformation was performed on all six variables: number
of genes in the pathway or group, number of unique genes (not present in any other pathway
or group), number of loci in the pathway bin, number of variants in the pathway bin, genomic
coverage of the pathway bin, and the BioBin reported Bonferroni adjusted p-value. Because
of the skewedness, any pathway bins that had transformed loci values outside of 2.5 standard
deviations of the log-transformed loci mean were removed.
Figure 27 and Figure 28 show the correlations between six untransformed and trans-
formed variables (with outliers removed), where each pairwise correlation is significant (p-
value < 0.05). A bin was considered an outlier if the number of loci in the bin was more
than 2.5 standard deviations from the mean transformed loci value.
The number of loci, number of variants, and size of genomic region were significantly and
linearly correlated with each other (correlation coefficients > 0.95). The most interesting
correlations were the nonlinear correlations between the loci/variants/genomic coverage and
p-values. Figure 28B is a higher magnification of the highlighted correlation in Figure 28A;
specifically, the correlation between log10 p-values and log10 variants were plotted. The
lowess smoothing function is shown in red, and the function appears to change slope twice.
On the x-axis, the slope from x=1 to x=3 is relatively linear and the log10 p-value increases
with an increasing number of variants (p-value becomes more significant). From x=3 to
x=4, the slope is near 0. From x=4 to x=5, the slope appears nonlinear and with a larger
slope than the left slope, indicating again most significant p-values with higher numbers
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Figure 27. Investigation of pathway significant correlation with bin size using untransformed
pathway variables. Correlation scatterplot matrix for six untransformed variables: the num-
ber of genes in a pathway (n genes), the number of unique genes in the pathway (n uniq), the
number of loci in the pathway bin (loci), the number of variants in the pathway bin (vari-
ants), the genomic coverage of pathway (coverage kb), and the bin p-value (p-val). Bins consid-
ered outliers were removed before generating the correlations (http://stat.ethz.ch/R-manual/R-
patched/library/graphics/html/pairs.html). The variables are right skewed and require transfor-
mation.
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of variants in a bin. Although these are transformed values, the p-values are not perfectly
uniform. Therefore, the tails are possibly unreliable.
Lastly, boxplots describing certain characteristics from each data source were created.
Figure 29 shows that specific sources (i.e. KEGG) consistently have larger bin characteristics
(number of loci, number of genes, coverage (kb), etc.) and also have much more significant
bin p-values (Figure 29B). It appears that certain sources might inherently have more
significant groups by nature of the information that these sources provide, or because of the
size of groups found in the source.
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Figure 28. Investigation of pathway significant correlation with bin size using log10 transformed
pathway variables. Correlation scatterplot matrix for six log10 transformed variables: the num-
ber of genes in a pathway (n genes), the number of unique genes in the pathway (n uniq), the
number of loci in the pathway bin (loci), the number of variants in the pathway bin (variants),
the genomic coverage of pathway (coverage kb), and the bin p-value (p-val). Bins considered out-
liers were removed before generating the correlations. Figure 28B is a higher magnification of
the correlation highlighted in Figure 28A, but instead of the +log10 transform of p-values, it is
showing the the log10 transformed p-values and log10 transformed variants with a loess smoothing
function (red line) and 95% confidence intervals (gray shading). (http://stat.ethz.ch/R-manual/R-
patched/library/graphics/html/pairs.html).
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Figure 29. Pathway characteristics presented by LOKI source. Different pathway characteristics
presented in box plots: A) The y-axis shows the log10 frequency of each source statistic for the
number of genes (Num. Genes), the number of loci (Num. Loci), the number of variants (Num.
Variants), and the coverage in kb, B) The distribution of p-values for the various knowledge sources.
On average, the same four sources listed above also tend to have bins with smaller p-values. Each
boxplot and color corresponds to the biological knowledge sources listed in the legend. KEGG,
NetPATH, PharmGKB, and Reactome show consistently larger bins (higher number of loci, variants,
and coverage).
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Discussion
1000 Genomes Project data
Since the reference genome is predominantly of European ancestry [98, 99, 100], populations
with non-European ancestry generally have more variation with respect to the reference
genome than populations of European ancestry (see Table 14). Therefore, to interpret the
results of this study, one might conclude that non-European populations have higher rates
of sequencing error than European descent populations. However, in the most recent 1000
Genomes Project publication, the authors report an accuracy of individual genotype calls
at heterozygous sites more than 99% for common SNPs and 95% for SNPs at a frequency
≥ 0.5% [60]. Furthermore, the authors found that variation in genotype accuracy was more
related to sequencing depth and technical issues than population-level characteristics [60].
Therefore, neither the sequencing error nor the predominantly European reference genome
adequately explain the trends seen in the genomic feature exploration.
Both sequence generation (technology and/or site) and population identity strongly
contribute to underlying stratification in next-generation sequence data. After removing
individuals with cryptic relatedness, 4 out of 14 Phase I populations were sequenced entirely
using a single sequence technology (CHB, CHS, JPT, and TSI). The other 10 populations
had between 3-18 individuals or 5%-57% of the population sequenced on technologies
other than Illumina (ABI SOLID or LS454). Note: all three of the Asian populations
(after removing individuals with cryptic relatedness) were sequenced only with Illumina
technologies.
Investigation of allele sharing
To identify cryptically related individuals, LD-pruned common variants (minor allele fre-
quency ≥ 5%, linkage disequilibrium r2 ≤ 0.2) were used to calculate identity-by-descent.
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Seventy-five individuals of various population backgrounds were identified and eliminated.
In addition to the previously documented relatedness in 1000 Genomes Project [http:
//www.1000genomes.org/phase1-analysis-results-directory], additional cryptic re-
latedness was found [90, 101]. The differences are likely because continental groups were
used (not a single population or the entire 1094 individuals) to identify cryptically related
individuals; in this analysis, continental groups could include variants with fixed opposite
frequencies that are overall common. This is infrequent in populations of the same conti-
nental group, but could be stratification introduced by different sequencing technologies.
Genomic feature exploration
The major goal of this study was to investigate population stratification across multiple
biological features. Matrix plots were created to illustrate the proportion of significant
bins in each comparison (shown in Figure 20, Figure 21, Figure 22, Figure 23, Figure 24,
and Figure 25). These results show an interesting trend between functional regions of the
genome and variant tolerance, where variant tolerance refers to the balance of mutation
load and resulting functional impact. Mutations appear to be less tolerated in functional
regions. Similarly, ECRs, which are known to be conserved among species, are also the
features least likely to have variation burden differences between two populations. There
is some debate about selection and functional significance in these conserved regions; it is
unknown what factors have the largest effect on mutation rates [102], but it is possible that
consistently low mutation rates in these features have generated conserved regions through-
out evolution [103]. There are two potential explanations: 1) additional level of repair of
DNA damage in transcriptional active regions by transcription coupled repair (TCR), 2)
approximately 3% of the genome is subject to negative selection; however, it is estimated
that functionally dense regions contain up to 20% of the sites under selection [102, 103].
A number of the top results in each comparison have an interesting context, particu-
larly in light of natural selection. Perhaps one of the most notable is SLC24A5 (Ensembl
ID:ENSG00000188467), which is one of the top ten results in 19 out of 91 populations
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comparisons in the gene feature analysis. European specific selective sweeps estimated in
the last 20,000 years suggest that SLC24A5 is key in skin pigmentation; Zebrafish with
“golden” mutations in this gene exhibit melanosomal changes [104, 105, 106]. The presence
of selection in this gene only in particular populations is most likely due to environmental
factors such as distance to the equator, which has led to the evolution and expansion of low
frequency variants in some populations but not others.
A second notable top result is DARC (Ensembl ID:ENSG00000213088), which encodes
the Duffy antigen. The DARC gene bin was in the top ten results in 14 out of 91 population
comparisons in the gene feature analysis. It has long been known that populations of African
descent have increased diversity due to natural selection at this location, which prevents
Plasmodium vivax infection.
The top result from the regulatory region analysis was a region on chromosome 20
(chr20:45395536- 45396346) which was in the top ten bins in 24 out of 91 population com-
parisons in the ORegAnno feature analysis. This region also overlaps several ENCODE
transcription factor binding sites in multiple cell lines: CTCF, POLR2A, NFYA, E2F1,
FOS, and more. It was also annotated as an insulator in multiple cell lines in ENCODE
Chromatin State Segmentation analyses using Hidden Markov Models [71, 107].
As one last example, the intergenic bin chr15.968 contains variants in the genome loca-
tion chr15:48400199-48412256. This bin is one of the top ten bins in 17 out of 91 population
comparisons in the intergenic analysis. The region covered by the chr15.968 bin is less than
1kb upstream of SCL24A5 on chromosome 15 and overlaps with several transcription factor-
binding sites (including CTCF), regions thought to be weak enhancers, and regions thought
to be insulators. According to Grossman et al., there are defined regions under natural selec-
tion before and after this region (chr15:45145764-45258860 and chr15:48539026-48633153),
and all are very likely to participate in the transcriptional regulation of SLC24A5.
The natural selection features require knowledge of three things for interpretation: 1)
population A, 2) population B, and 3) the population where this signature was identified.
When all three of these are within the same ancestral or continental group, very few differ-
ences are expected in low frequency burden. However, if population A is the same or similar
to the population possessing the selection signature and population B is different, signifi-
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cant differences are expected in low frequency burden between population A and population
B. In these results, the vast majority of regions considered to be under natural selection
had significant differences in low frequency burden between disparate ancestral populations,
which supports the theory of selection in these regions.
Proportion of LD between variants in a bin
Low frequency variants can form rare haplotypes, which inflate the signal in a feature
bin [43, 97]. The top 10 ranked bins from the CEU-CHB, CHB-YRI, and CEU-YRI coding
and noncoding analyses for presence of LD between two variants in the same bin were
investigated. Figure 26 shows bins predominately filled with white-space indicating low
to no pairwise LD between variants in those bins. In the top ten bins from these three
analyses, rare haplotypes do not appear to be driving the significant differences seen in low
frequency variant burden.
Pathway size correlations
In general, size of bins can influence the number of stratified variants contained and thus
the significance of that bin. It is important to prove that this is because larger bins have
a greater opportunity to collect variants that are stratified and not because of inflated
type I error. Type I error rates in bins between approximately 40 variants to over 100,000
variants were tested and no correlation between bin size and Type I error rate was found
(see Chapter IV). However, it should also be noted that while larger bins have more chances
to collect stratified variants, there is also a larger capacity to collect neutral variants that
contribute noise and decrease the signal.
Using CEU-YRI pathway burden analysis, correlation between pathway size and signif-
icance was reviewed. The number of genes in pathways ranged from 1 to over 700 genes,
with the average around 5 genes per group. Correlations for this data are shown in Fig-
ure 28. Not surprisingly, there were very linear and positive correlations between number
of loci, number of variants, and genomic coverage. However, each of these had a nonlinear
and somewhat complex relationship with the log-transformed p-value. This is highlighted
in Figure 28B, which shows the relationship between the log10 transformed p-value and
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the log10 transformed number of variants in the bin. The trend indicates that p-values are
positively correlated (become more significant) with numbers of variants in a bin when the
numbers of variants are relatively small or very large.
Two reasons could explain this correlation: 1) the false-positive rate is influenced by bin
size (number of variants per bin), and 2) true signals from child bins (genes) with burden
differences which perpetuate higher numbers of significant parent bins (pathways). After
extensive simulation testing (see Chapter IV) and recent publications in the literature, the
latter is likely true [108]. A single or small number of child bins (gene bins in this example)
can drive parent bins (pathways in this example) to be significant even if no other child
bin contains stratification. The comparison in Figure 29 between group sources available
in LOKI suggests KEGG, NetPATH, PharmGKB, and Reactome have consistently larger
bins (higher number of loci, variants, and coverage). On average, these same four sources
also tend to have bins with smaller p-values. Therefore, larger pathways are more likely to
contain a gene with extreme low frequency variant stratification.
Trends in the Asian continental group
The x-axis of each matrix plot (i.e. Figure 20) is oriented with African continental popula-
tions on the far right and the continental group with the highest proportion of significantly
different low frequency variant bins on the far left. Asian populations are generally more
different from African populations than European populations. There are at least three
possible explanations; first, the Asian populations were the only continental group to be se-
quenced on the same technology, which could introduce a different bias when testing any of
these populations with populations outside of Asian ancestry. While this is true of the 1,019
unrelated individuals, there were cryptically related individuals sequenced using SOLID
technologies in all three of the Asian populations. The only population (including crypti-
cally related individuals) to be sequenced exclusively on Illumina was TSI. When the Asian
populations were examined, the cryptically related individuals were added back into the
analysis to see if individuals of Asian descent sequenced with different technologies changed
the results. The trend was the same, Asian populations are the most different from African
populations with regard to low frequency variant burden. The second potential explanation
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is that Asian populations had considerable proportions of cryptic relatedness that had to
be removed for this analysis, 49 of the 75 individuals removed were from Asian populations.
Perhaps there was something unique about how those samples were collected. The third
and most interesting explanation involves the journey for early Asian populations leaving
Africa. Travelling east was much different geographically than travelling west. For exam-
ple, early Asian migrants would have traversed the Himalayan Mountains. The harsh travel
could have induced bottlenecks and other evolutionary mechanisms that would uniquely
change the genetic architecture, specifically the architecture of low frequency variation.
Conclusion
As researchers continue in pursuit of genetic etiologies explaining heritability in common,
complex disease, it is important to consider multiple types of genomic data, specifically vari-
ation beyond common variants. Low frequency variants are more frequent in the genome
than common variants and are likely to have significant functional impact on human health.
Many successes are expected in next-generation data analysis; however, it has become in-
creasingly clear that the same methods and corrections used in GWAS cannot be applied
to low frequency variant analyses. Since low frequency variants are often recent mutations,
they are specific to continental ancestry groups. This provides two important conclusions:
first, low-frequency variants that influence disease are likely not the same across distantly
related individuals (allelic and locus heterogeneity); second, low frequency population sub-
structure leads to substantial differentiation and cannot be ignored in low frequency anal-
yses [60].
Population stratification is a pertinent and very present confounder in genomic stud-
ies. In common variant association studies, stratification is often managed using ances-
try correction components. Until relatively recently, the challenges presented by low fre-
quency population stratification to genomic analyses has been overlooked. Current methods
used for GWAS to correct for ancestry are not likely adequate for low frequency stratifi-
cation [76, 109]. Therefore, it is imperative that researchers are aware of potential pitfalls
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stratification can introduce to low frequency genomic analyses. Additionally, this study
highlights potential limitation in using the 1000 Genomes samples as population based
controls in case-control association studies. If the case population belongs to a different
ancestry than the 1000 Genomes control population and/or they are exclusively sequenced
using a different technology, this can introduce significant stratification. This level of strat-
ification may or may not be adequately corrected using PCA or other analysis methods.
Thus, it is clear that proper evaluation of stratification would be prudent if 1000 Genomes
Project data are being proposed as a population control set.
In summary, the results presented in this chapter expose the magnitude of low frequency
population stratification between all populations available in 1000 Genomes Project Phase
I release across multiple interesting biological features. The magnitude of low frequency
stratification appears to be dependent on the functional location of the variation. For ex-
ample, there were fewer differences in low frequency burden in coding regions than intergenic
regions. Features with less variant tolerance and possibly more evolutionary constraint had
fewer differences in low frequency variant burden between different populations, i.e. sig-
nificant low frequency bins seemed to be consistent with mutation theory. African descent
populations overall varied most greatly from populations of Asian descent. However, low
levels of stratification existed even between populations of the same continental group. Fu-
ture studies should focus on methods to accurately control for low frequency population
stratification.
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CHAPTER VI
BIOBIN ANALYSES IN NATURAL DATA
Kabuki analysis
BioBin was applied to ten samples with Kabuki syndrome. Kabuki syndrome is a rare
disorder that affects multiple systems; it is commonly associated with the following char-
acteristics: cardiac anomalies, skeletal abnormalities, characteristic facial appearance, and
intellectual disability [110]. In a published analysis using these data, Ng et al. applied a
filtering method to identify MLL2 as a possible causative gene for Kabuki syndrome [111].
Although a sample of ten individuals across multiple ancestries do not provide reasonable
power to achieve statistical significance for identified rare variant trends in a burden analy-
sis, it was a useful exercise to show how BioBin can be used to prioritize bins based on rare
variant burden differences.
Study sample
The NHLBI Kabuki dataset available on dbGaP (http://www.ncbi.nlm.nih.gov/gap/) was
downloaded April 2012. According to the authors of the original study, ten unrelated
individuals with Kabuki syndrome were sequenced: 7 of European ancestry, 2 of Hispanic
ancestry, and one of mixed European and Afro-Caribbean ancestry [111]. Variants were
identified using a custom Agilent array capture kit targeting all protein coding regions
annotated by RefSeq 36.3 [111]. Shotgun fragment libraries were hybridized to these custom
microarrays, and then enriched using massively parallel sequencing for an average coverage
of 40x on the mappable, targeted exome [111]. The raw fastq files were downloaded from
dbGaP and processed using standard exome algorithms: bwa, samtools, picard, GATK, and
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bedtools.
Since the number of identified variants correlate with the depth of coverage (to a thresh-
old of approximately 30x) and the Kabuki cases are from multiple ancestral backgrounds, it
was imperative to use a multi-ethnic control set with a high depth of coverage. Publically
available Complete Genomics whole-genome sequences for 54 unrelated individuals from 11
populations were used as the control group for this experiment [112]. The 54 Complete
Genomics samples were sequenced with an average genome-wide coverage of 80x [112].
Methods and results
In this study of 10 cases and 54 controls, there was very little power to detect a reasonable
association. If the probability of exposure (allele frequency) was 0.03, type I error was 0.05,
and the true odds ratio for disease in exposed subjects relative to unexposed subjects was
3, the power to reject the null hypothesis using a chi-square test was only 0.226 [113].
BioBin was used to collapse the whole-exome data for 10 Kabuki individuals with 54
individuals from Complete Genomics whole-genome data. In the original Kabuki analysis,
Ng et al. used a filtering method to identify MLL2 as a possible causative gene for Kabuki
syndrome. In this analysis, in order to compare the cases and controls, we filtered both
datasets by exome boundaries (available from UCSC) and filtered out variants present
in the 1000 Genomes Project Phase I data (October 2011 release: 14 populations, 1094
individuals) [71, 88]. A MAF binning threshold of 0.05 was used to collapse rare variants
based on known gene regions (start and stop positions form bin boundaries) and known
pathways (gene bins in the same pathway are collapsed into one pathway bin). BioBin
produced the MLL2 gene bin with 125 total variant loci (184 total variants) at a minor
allele frequency threshold of 0.05, but was not significant (p-value = 0.4718).
While we did not replicate the MLL2 finding, one of the top pathways included EMG1,
a gene previously associated with Bowen-Conradi syndrome (pathway adjusted p-value <
0.001, gene adjusted p-value < 0.001). Bowen-Conradi syndrome has a much more severe
phenotype, but shares two disease characteristics with Kabuki: impaired growth and mental
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retardation [114].
Conclusions
Ng et al. filtered out 1000 Genome variants and other non-causative variants identified from
previous Kabuki studies. They also considered only nonsynonymous variants with predicted
changes in function. As shown in the results section, ten individuals with whole-exome data
are not a large enough case sample size for sufficient power in a Wilcoxon 2-sample rank
sum test. The uneven sample size and different sequencing approach for cases and controls
were major limitations in this study. To compare the cases and controls, both datasets
were filtered by exome boundaries and variants present in the 1000 Genomes Project Phase
1 release were removed. These steps helped reduce potentially noise contributing neutral
variants.
The same filtering process from Ng et al. was not used and the sample size affords
very little power for a case-control study, which together, likely explain why MLL2 was
not significant in this analysis. In addition, population stratification exists in the cases and
controls and was not accounted for in this analysis. MLL2 has 54 exons and quite a bit of
neutral variation. As shown in Chapter IV, larger bins with increased background variation
make causative signals harder to detect.
In this underpowered analysis, BioBin results should be utilized as a prioritization
method; thus, it would require a much larger sample size to investigate the robustness
of the EMG1 association. To improve this analysis, one could potentially use a principle
components analysis to adjust for the variant confounding between the two groups in a
regression analysis or perform a permutation test to help adjust for unknown confounding.
A better test data set would include at least 500 individuals that were sequenced with the
same technology. Overall, BioBin can be used as a filtering mechanism to group data and
evaluate rare variant burdens between two groups, but requires a more substantial sample
size to gain power to detect significance.
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Cystic fibrosis analysis
Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems. According to the
Cystic Fibrosis Foundation, cystic fibrosis affects approximately 1 out of every 2000-3000
live births in Caucasian individuals and the median life expectancy for patients with cystic
fibrosis in 2011 was 36.8 years [115]. It is caused by homozygous or compound heterozygous
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, a
regulated chloride channel. More than 1500 catalogued mutations with disease causing
potential in the CFTR gene have been catalogued [116]. Of the various complications
and comorbidities that accompany CF, the most debilitating organ dysfunction involves
abnormalities in airway secretion and resulting chronic lung infections.
Pseudomonas aerunginosa (PA) infection is the most common cause of respiratory fail-
ure in patients with CF, and is responsible for deteriorating lung function and mortality in
patients with persistent infection [117]. Although there are clear environmental exposures
that contribute to infection frequency, there are also genetic factors that modify recurrent
PA infection risk. Recently, Green et al. calculated the heritability of chronic PA infection
as 0.76 using monozygotic and dizygotic twins with Class I, II, and III mutations (severely
affected CFTR function) [118]. The results of this study and the known severity of chronic
infection to individuals with cystic fibrosis make a strong case for continued genomic re-
search in this area.
Study sample
Data were accessed from the National Heart, Lung, and Blood Institute (NHLBI) from
September 2012 through January 2013. Study Accession ID phs000254.v2.p1 contains ex-
ome sequence data from 431 subjects across two cohorts, 189 limited to cystic fibrosis
research from the University of Washington (UW) and 242 for general research use from
University of North Carolina (UNC). Selected subjects were divided based on two extremes
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Table 20. Data characteristics for cystic fibrosis study sample for 416 European descent individuals.
Covariates
Overall (%) PA (%) PF (%)
N=416 N=181 N=235
Data release version
Phase I 90 (21.63) 90 (49.72) 0 (0)
Phase II 326 (78.37) 91 (50.28) 236 (100)
Sample Site
UW 174 (41.83) 117 (64.64) 58 (24.58)
UNC 242 (58.17) 64 (35.36) 178 (75.42)
of lung disease phenotypes: youngest individuals with chronic Pseudomonas aeruginosa
(Pa) and those exhibiting extremely poor pulmonary function (PF) as defined by survival
corrected FEV percentile [119].
Before starting analyses, a principal component analysis (PCA) was run using the 1000
Genomes Project Phase I data and CF data to assess and designate ancestry [88]. Figure 30
shows the first two principal components of the merged 1000 Genomes (labeled by color in
legend) and dbGaP cystic fibrosis study data (labeled gray in legend). In Figure 30, indi-
viduals of European descent from the 1000 Genomes Project data are clustered in orange.
In the cystic fibrosis dataset, individuals with values for PC1 ≤ 0.005 or PC2 ≤ 0.01 were
eliminated from the data set based on how closely individuals clustered with the European
descent group from 1000 Genomes Project Phase I data. Using these criteria, 15 individuals
from the UW site were dropped from further analyses.
Table 20 shows phase and site data characteristics of the remaining 416 individuals.
Phase refers to the dbGaP release, 90 individuals used in this study were released in the
first phase through dbGaP. An additional 326 individuals were released in the second phase.
All of the individuals from the PF study were ascertained in the second phase. In addition
more individuals overall were collected from the UNC site than the UW site.
All 416 samples were collected from individuals with cystic fibrosis, but technically from
two studies: recurrent Pseudomonas aeruginosa (PA) infection and pulmonary function
(PF) phenotype. Therefore, the analyses presented in this chapter are stratified by pheno-
type. Several of the covariates were measured over the clinical history for a given patient;
in this case, median values were used for statistical analyses. Median values were used for
the following variables: Forced Expiratory Volume (FEV) measures, age, and height. The
113
Figure 30. Principal component analysis (PCA) using merged samples from the CF analysis and
1000 Genomes Project Phase I data to identify ancestry.
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Table 21. dbGaP cystic fibrosis clinical and demographic characteristics for two studies: recurrent
pseudomonas infection (PA) and mild/severe pulmonary phenotype (PF).
Covariates
PA∗ PF
Cases Controls Cases Controls
Gender†
Male 38 51 58 60
Female 49 43 56 62
Age‡
Male 5.95 (2.89) 15.92 (7.50) 12.12 (3.45) 19.24 (6.83)
Female 5.68 (2.53) 14.28 (5.51) 13.56 (3.98) 19.52 (8.85)
FEV values∗‡
Male 1.33 (0.54) 2.15 (0.92) 1.27 (0.49) 3.71 (0.86)
Female 1.39 (0.53) 2.01 (0.59) 1.16 (0.40) 2.86 (0.57)
Height (cm)∗‡
Male 124.87 (11.73) 159.65 (19.15) 145.77 (17.75) 165.17 (14.13)
Female 127.30 (13.67) 150.77 (11.21) 148.8 (14.81) 155.17 (12.29)
Sequencer (HiSeq)†
Male 7 6 26 30
Female 7 7 28 23
Sequencer(GAII)†
Male 31 45 34 33
Female 42 36 33 41
† counts (N)
‡ calculated mean and standard deviation
∗ Values inclusive of imputed measures
clinical and demographic variables shown in Table 21 are stratified by study and gender.
To maximize the number of individuals in each statistical analysis, missing values were
imputed for any covariates with missingness. FEV values and height variables were missing
in 14 PA cases and are annotated with an “∗” in Table 21. The R package “mi” was
utilized to perform multiple imputations [120]. Although, these were not missing completely
at random, the variables were highly correlated with age and gender, thus, this process
provided a reasonable imputation. A fixed estimate for imputed values was used in the
analysis.
Correlations between covariates shown in Table 20 and Table 21 were evaluated. The
correlation plot shown in Figure 31 was generated using the R package “PerformanceAn-
alytics” to visualize the correlation between all of the study covariates, clinical covariates,
demographic covariates, and calculated principal components in the PA study [121, 122].
On Figure 31, the bottom panel contains the scatterplots between pairwise variables, each
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label and histogram are shown along the diagonal, and the top panel indicates the coeffi-
cient of correlation (in number and relative size) and the significance of the correlation in
asterisks. As shown in Figure 31, the first principal component was highly correlated with
both sequencing variables. Covariates age, FEV measurements, height, and gender were
correlated. This is not surprising since lung capacity is anatomically related to individual
size.
The comprehensive correlations from the PA analysis shown in Figure 31 are some-
what hard to study in detail, pertinent correlations shown in Figure 31 are shown again in
Figure 32.
Methods
As healthcare providers continue to adopt electronic medical record systems and build col-
laborations with researchers, genomic study designs will increasingly include a multitude of
genomic and clinical data. Many of these variables are highly correlated measures that can
complicate analytical results. Using the CF dataset, the following approaches were taken
with the CF data: traditional binning approach with logistic regression using maximum-
likelihood estimators (ML) and logistic regression using penalized likelihood estimators
(Firth), pre-processing variable selection approach with ML logistic and Firth logistic re-
gression, pathway analysis using ML logistic and Firth logistic regression, and a machine
learning elastic net analysis.
Statistical analyses
Firth logistic regression performs better than ML logistic regression in analyses with “sep-
aration.” Separation occurs when the outcome is very rare, very common, or when there
are several correlated predictors. In small data sets, separation occurs when both outcomes
are not observed in a cell defined by two covariates, e.g., the outcome is perfectly predicted
by a non-trivial combination of covariates. Perfect separation refers to a combination of
predictors that perfectly predict the outcome. For example, zero controls (outcome) are
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both female (independent variable) and ever-smokers (independent variable). Separation
can also occur if the outcome variable can be perfectly separated by a single independent
variable. In logistic regression using maximum likelihood estimators, this causes problems
fitting the model and results in at least one of the parameter estimates diverging to infinity
(infinite log p-values). Occasionally this can cause an error; however, most of the time,
the only diagnostic clue is unreliable standard error estimates, i.e., Wald test confidence
intervals of infinite width. Firth introduced a modified score equation to include a penalty
function which reduces bias and resolves the issue of separation. It is generally preferred
to exact conditional regression because it can be implemented in cases of continuous and
categorical variables and requires less computational power than exact conditional regres-
sion [123, 124, 125]. Firth regression was implemented using the R package “logistf” [126].
For each analysis, logistic regression used a maximum likelihood estimator (ML) and Firth
logistic regression used a penalized likelihood estimator.
Elastic net analysis refers to a regularized regression method that can perform variable
selection and prediction using a variety of parameter optimizations, bootstrapping, and/or
cross validation. It is ideal when there are more predictors or modeling parameters than
samples. Elastic nets use two penalty parameters, alpha (α) and lambda (λ), to shrink coef-
ficients of inconsequential predictors and optimize coefficients for relevant predictors [127].
Although using a machine learning approach to select variables introduces bias to the anal-
ysis, it helps maintain reasonable error by building parsimonious models.
To perform variable selection, an elastic net algorithm was used to rank variables that
model the phenotype; genetic data was not used to perform variable selection [128, 129].
For each phenotype, PA and PF, subsets of the covariate data were used in repeated cross
validations to estimate optimal alpha and lambda parameters with minimal cross validation
error. Once the optimal alpha and lambda values were obtained, 1000 models were built
from bootstrap samples of the data. Variables that appeared in over 75% of the generated
models were considered high priority and likely important predictors for the phenotype of
interest. A threshold of 75% was an arbitrary designation to reduce noise from unimportant
variables but still be fairly inclusive of any variables that consistently showed up across 1000
models. Depending on the alpha and lambda parameters chosen, the elastic net algorithm
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can perform variable selection and also allow for correlated variables to remain in the model.
For example, two highly correlated variables can be present in 85% and 90% of the 1000
bootstrapped models. As discussed before, correlations in covariates can lead to unstable
error estimates in a logistic regression analysis. Therefore, the last statistical iteration
included pruning the selected covariates using correlation measures to produce a minimally
correlated subset of variables. Adjusting first for the subset of covariates and secondarily the
selected and pruned covariates, statistical analyses were performed to detect an association
between the outcome and each bin from BioBin.
Lastly, elastic net models were generated using all available covariates and low frequency
bin data. In this more traditional application of elastic net, 10 cross validations were per-
formed. First, subsets of the data were split into training (0.632) and testing sets. For each
training set, 500 bootstrapped samples were used to estimate optimal alpha and lambda
parameters with minimal cross validation error and to build a final model. Prediction ac-
curacy, sensitivity, and specificity measurements were obtained by applying the final model
to the testing set. This process was completed independently over 10 cross validations. The
final models, selected variables, coefficients, and accuracy from each cross validation were
compared.
In addition to varying binning parameters and statistical tests, various subsets of co-
variates were used to adjust the analyses. Each analysis was tested without adjusting for
any covariates, adjusting only with significant principal components (with respect to ex-
plaining genetic variance), adjusting with all available covariates, adjusting for covariates
based on variable selection, and adjusting for covariates based on variable selection and
then pruned using correlation between covariates. Significant principal components were
calculated using the Tracy-Widom statistic available in the Eigensoft package [130].
BioBin parameters
BioBin has a number of configurable parameters when performing analyses. These are
described in Chapter III. In the following analysis examples, a binning threshold minor
allele frequency of 5% was chosen. Gene bin analyses were performed using “no weight”
and “minimum weight” approaches. Several of the analyses described use filters to separate
120
variants based on function. Nonsynonymous variants and predicted damaging variants were
calculated using the Ensembl Variant Effect Predictor (VEP), which includes results from
SIFT and PolyPhen-2 [72, 73, 74, 75]. A variant was labelled “damaging” if SIFT or
Polyphen-2 identified the variant as damaging at any level (SIFT: “deleterious”, PolyPhen-
2: “possibly damaging”, “probably damaging”).
The CF exome data were binned based on gene regions determined by the NCBI Entrez
gene source [61]. Depending on the analysis (PA or PF), approximately 15,000 gene bins
were created. Several binning strategies were used: minimum weights or no weights, nonsyn-
onymous variant filters, deleterious variant filters, and functional variant filters. Functional
variant filters combined all nonsynonymous variants in a bin, but assigned custom weights
to increase the influence of nonsynonymous variants (1.1) and predicted deleterious variants
(1.2).
Pathway analyses were performed using multiple sources available in LOKI (see Chap-
ter III). Similar parameter sweeps and statistical methods were applied to pathway analyses
as previously described for the gene feature analyses.
Results and discussion
Pulmonary function phenotype
The pulmonary phenotype analyses were performed on 114 cases (severely affected pul-
monary function) and 122 (mildly affected pulmonary function) controls. Several of the
covariate measures were highly correlated with the phenotype, including FEV measure-
ment, age, and height. The impact of covariate correlation is very important to result
interpretation. For instance, when one of the covariates is highly predictive of the phe-
notype, separation can occur. Correlations between two or more “independent” variables
can lead to a non-uniform p-value distribution and possibly an increase of false-positive
results. In Figure 33, quantile-quantile plots (QQ plots) are shown for a few results from
the pulmonary function analysis. In this analysis, no variant weight was used and only
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nonsynonymous variants were binned.
Figure 33a shows the unadjusted QQ plot, which does not quite fit the expected uniform
distribution. Figure 33b shows the QQ plot adjusting for covariates listed in the caption.
This plot is highly abnormal; all of the expected log p-values are 0. In the results, these are
actually infinite log p-values. Figure 33c shows the QQ plot adjusted for ONLY covariates
using variable selection (without correlation pruning). Lastly, Figure 33d shows the same
data as Figure 33c except using a Firth logistic regression instead of a maximum likelihood
estimated logistic regression which is sensitive to separation.
In the example shown in Figure 33b, the offending covariate is FEV, which was correlated
to the measure used to phenotype individuals as severe or mild phenotypes and highly
correlated to height and age. If a correlated predictor variable is critical to the analysis, one
can use Firth regression, a penalized maximum likelihood estimator which better estimates
coefficients and standard errors in cases of perfect or near perfect separation. As shown
in Figure 33d, the penalized regression manages error much better than standard logistic
regression and produces more uniform log p-values.
After evaluating the p-value distribution of models which used the ML logistic regression,
variable selection with correlation pruning that included only significant principal compo-
nents best resolved the issue of separation, i.e., two or more correlated predictors were not
perfectly predicting the outcome. There were no highly significant hits from the PF gene
bin analysis, which might be expected given the small sample size and data stratification
present, e.g. different sequencing technologies, study phase, study sites, etc. However, Firth
regression provided the most reliable results. A few of the top ranked results were biolog-
ically relevant and interesting (results are shown in Table 22). The p-values provided for
each bin are uncorrected for multiple testing, such as Bonferroni correction. This analysis
adjusted for selected covariates pruned for correlation or significant principal components,
using no variant weights, and binning only nonsynonymous variants.
None of the results shown in Table 22 are significant after Bonferroni correction. A few
of the results PPP1R9A, EPS8L1, and FERMT1 are categorically related to cytoskeletal
structure, which is potentially pertinent since severely affected lung phenotypes are likely
to be fibrotic. Two other results involve ion channels, SGK3 is a protein kinase involved
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(a) Unadjusted analysis (b) Adjusted for all covariates
(c) Adjusted for select subset of uncorrelated co-
variates
(d) Adjusted for all covariates using FIRTH re-
gression
Figure 33. Quantile-quantile plots for pulmonary function (PF) analysis illustrating effect of perfect
separation in PF data. (a) QQ plot for unadjusted gene bin analysis using ML logistic regression.
(b) QQ plot for adjusted gene bin analysis using ML logistic regression, analysis adjusted for top
10 principal components (PC), gender, sequence technology, FEV measurement, age, height, and
site (c) QQ plot for adjusted gene bin analysis using ML logistic regression, analysis adjusted for
selected variables from elastic net ranking and post-ranking elimination of highly correlated variables:
PC1, PC8, PC9, PC10 and height (d) QQ plot for adjusted gene bin analysis using FIRTH logistic
regression, analysis adjusted for top 10 principal components (PC), gender, sequence technology,
FEV measurement, age, height, and site
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with ion channel regulation. However, another member of the SGK family, SGK1, regulates
CFTR conductance [134, 135]. Lastly, ANO4 is a calcium-mediated chloride ion transport,
essential for Cl- secretion in epithelial cells, smooth muscle peristalsis, and olfactory sig-
naling. The relationship between ANO4 and CFTR has been tested in mice but requires
further research [136].
Recurrent Pseudomonas aeruginosa phenotype
The PA phenotype analyses were performed on 87 cases and 94 controls. Again, many of
the covariates were highly correlated. In Figure 34, quantile-quantile plots (QQ plots) are
shown for few of the results from the PA analysis. The expected log p-values from a uniform
distribution are shown by the red line, observed log p-values are shown in black. In the
particular analysis shown, all nonsynonymous variants were binned with a functional weight
applied, i.e., nonsynonymous variants received a weight of 1.1 and predicted deleterious
variants received a weight of 1.2.
As shown in Figure 32, median age, median FEV measurement, and median height
are correlated in the PA data. Figure 34a shows the unadjusted QQ plot, which does
not quite fit the expected uniform distribution. Figure 34b shows the QQ plot adjusting
for all possible covariates (listed in the caption). This plot has an unusual observed p-
value distribution with several observed infinite log p-values. Figure 34c shows the QQ
plot adjusted for ONLY covariates using variable selection (without correlation pruning).
Figure 34d shows the QQ plot adjusted for covariates using variable selection and correlation
pruning. In this case, site and height variables were dropped due to high correlation with
other selected variables. Figure 34e shows the QQ plot after adjusting for only significant
principal components using the Tracy-Widom statistic [130]. Lastly, Figure 34f shows the
same data as Figure 34d except using a Firth logistic regression instead of a maximum
likelihood estimated logistic regression which is sensitive to separation.
After evaluating the p-value distribution of models which used the ML logistic regression,
variable selection with correlation pruning and using only significant principal components
best resolved the issue of separation. However, Firth regression provided the most reliable
results. A few of the top results using Firth regression are listed in Table 23.
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(a) Unadjusted analysis (b) Adjusted for all covariates
(c) Adjusted for select covariates (d) Select covariates and pruned
(e) Significant principal components (f) Select covariates-FIRTH regression
Figure 34. Quantile-quantile plots for Pseudomonas aeruginosa infection (PA) analysis (a) unad-
justed gene bin analysis using ML logistic regression, (b) adjusted for top 10 principal components
(PC), gender, sequence technology, FEV measurement, age, height, site, and PA culture using ML
logistic regression, (c) gene bin analysis adjusted for selected variables from elastic net ranking using
ML logistic regression, (d) adjusted for selected variables from elastic net ranking and post-ranking
elimination of highly correlated variables using ML logistic regression,(e) ML logistic regression ad-
justed for significant principal components (PC), (f) FIRTH logistic regression adjusted for same
variables as Figure 34c.
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There is only one significant result from the PA gene bin analysis after Bonferroni
correction, which might be expected given the small sample size and the aforementioned
data stratification present (e.g., different sequence technology variables, phase variables,
site variables, etc). However, some of the top ranked results were biologically relevant and
interesting. Results from a PA analysis adjusting for selected covariates pruned for correla-
tion or significant principal components, using minimum variant weights, and binning only
nonsynonymous variants are shown in Table 23. The p-values for each bin are unadjusted
for multiple test correction, i.e. prior to a Bonferroni correction.
Several factors are important to consider when interpreting these results; significance,
bin size, and direction of effect. Only ACER3 meets significance after a multiple test
correction. With only two loci in the bin, and particularly because one group (cases) does
not have any variants in this bin, it is important to consider stratification. This could be
explained with sequence technology differences or differences in variant calling.
Many results appear protective of recurrent PA infection, i.e., there are more variants
in controls than cases. The number of variants in each group shown in Table 23 is the sum
of variants in that particular group. In the PA analysis, the sample size is uneven, there
are seven more controls than cases. Therefore, the sum of variants shown in Table 23 does
not immediately translate to effect size.
Some results listed in Table 23 do not appear to have any extensive relationships with
infection, CFTR, or cystic fibrosis in the literature but do have some relevancy. For ex-
ample, SMG6 encodes a protein responsible for nonsense mediated decay (NMD), which
is the mechanism used to degrade defective CFTR proteins with premature stops. How-
ever, there is no literature supporting a direct association of SMG6 with cystic fibrosis
or infection [138]. Another example is FAM120A. According to IntAct, a database of in-
teracting proteins, FAM120A physically interacts with the CFTR protein according to an
“anti bait coimmunoprecipitation” experiment, but there is no literature further defining
this relationship [139]. The last example is MLLT4, which does not contain any direct links
in the literature to CF, but is associated with elevated states of immune response. This is
potentially interesting since much of the damage to lung epithelial cells is caused by chronic
inflammation and bacterial response.
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A few of the results in Table 23 have more relevant relationships with cystic fibrosis,
CFTR, or infection. Three are discussed in further detail below.
The ACER3 bin contains only two variant sites and was the only bin to remain signifi-
cant after Bonferroni correction. ACER3 encodes an alkaline ceramidase that metabolizes
ceramide to form lysolipid sphingosine. Both ceramide and sphingosine are signaling lipids;
ceramide is involved in inflammation and apoptosis and sphingosines primarily induce cell
proliferation and differentiation. Severe mutations in ceramidases can lead to lysosomal
storage disease, but an imbalance between ceramide and sphingosine can lead to an ac-
cumulation of ceramide and cell death on lung epithelial cells [140, 141]. Teichgra¨ber et
al. published the pioneer observation of ceramide accumulation. In Cftr -deficient mice,
an accumulation of ceramide in pulmonary epithelial cells resulted in age-dependent pul-
monary inflammation, death of respiratory epithelial cells, deposits of DNA in bronchi and
high susceptibility to severe Pseudomonas aeruginosa infection. In their particular mouse
model, heterozygous genetic deficiency of acid sphingomyelinase (Asm) or administration
of an Asm blocker, such as amitriptyline, normalized pulmonary ceramide and prevents
all pathological findings, including susceptibility to infection [140]. In humans, acid sphin-
gomyelinase (SMPD1 ) proteins convert sphingomyelin to ceramide [133].
In Table 23, DHCR7 has more variants in controls than cases. DHCR7 encodes the
enzyme 7-dehydrocholesterol reductase that catalyzes the conversion of 7-dehydrocholesterol
to vitamin D3 using sunlight. Recent results suggest that DHCR7 has been under selection
in recent evolutionary history to allow European populations to avoid severe vitamin D
deficiency as populations moved away from Africa and the equator. In the setting of cystic
fibrosis, which is predominant in Caucasian populations, this is quite interesting. However,
even more interesting are the implications of vitamin D deficiency, which include: cancer,
autoimmune disease, infection, and cardiovascular disease [137]. Active vitamin D is a
immune modulator; in an example by Holick, immune cells exposed to Mycobacterium
tuberculosis up-regulate the vitamin D receptor gene. Increased production of active vitamin
D produces cathelicidin, a peptide that can destroy many infectious agents. Low serum
levels of active vitamin D prevent this innate immune response, which results in increased
and more aggressive infections [142].
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Lastly, CYBA is considered. Inflammation in the lung epithelial cells in patients with
CF begins at an early age and is predominated by neutrophils. In CF patients, the persis-
tent inflammation fails to resolve the recurrent bacterial infections. It is thought that the
damage caused by neutrophils in CF is due to excessive reactive oxygen species production,
thus inducing airway damage and promoting bronchiectasis and fibrosis in the lungs [143].
In Table 23, CYBA is shown to have more variants in cases than controls. CYBA has
been previously associated with autosomal recessive chronic granulomatous disease (CGD),
characterized by a lack of reactive oxygen production in neutrophils to kill pathogens, re-
sulting in a diminished immune system and excessive bacterial and fungal infections [144].
Excessive or lack of reactive oxygen species production by neutrophils can cause chronic
and severe infection.
Pathway and elastic net analyses
Lastly, a pathway burden analysis was compared to an elastic net approach using PA data.
Again, none of the pathway results were significant after Bonferroni correction for multiple
testing. Most of the top ranked results were BioGrid interaction groups; many had at least
one bin from the top hits listed in Table 23. A few were unique signals, for example, Bi-
oGrid ID:637466 represents a physical interaction between CKS2 and LDHB. Cyclin kinase
2 plays a critical regulatory role in meiosis and mitosis. Abnormal expression has been
associated with many types of cancer [145]. Lactase dehydrogenase B encodes a subunit of
lactase dehydrogenase, which converts pyruvate to lactate and NAD to NADH. The expres-
sion of LDHB can also be unregulated in cancers [133]. Another top hit included BioGrid
ID:120309, which represents a physical interaction between CTPS2 and SPG21. CTPS2
encodes a catalyzing enzyme to convert CTP to UTP and deamination of glutamine to glu-
tamate. Cells with increased cell proliferation also exhibit increased activity in CTPS2 [71].
The protein encoded by SPG21 binds to CD4 to repress T cell activation. A mouse knock-
out of SPG21 had almost two fold difference of CFTR expression in brain tissue [146], but
a clear relationship for how these interactions might be linked with chronic PA infection is
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unclear. SPG21 could regulate CFTR expression or this could be a false positive result in
the expression data, future studies are needed to confirm.
In the 10 cross-validations of the elastic net, only two yielded models with non-zero
coefficients. The accuracy of both models in the respective test data set was 89%, but
there was only one coefficient common to both models, PPAP2C. PPAP2C is a member of
the phosphatidic acid phosphatase family (PAP). The function of this PAP is to convert
phophatidic acid to diacylglycerol, participate in de novo synthesis of glycerolipids, and
phospholipase mediated signal transduction [71]. It is also involved in the sphingolipid
metabolism described in the previous section for ACER3.
In one of the two models formed during cross validations, there were six non-zero coef-
ficients. Three of which could be distantly mapped using IMP [147] to genes related to cell
cycle. The network for CDK2, PPAP2C, and DNAJC9 is shown in Figure35. CDK2 is a
member of the Ser/thr protein kinase family, it is important for G1/S phase transition in
the cell cycle. DNAJC9 encodes a heat shock protein that can also map back to cell cycle
regulation.
Conclusions
Care must be take to exclude or manage highly correlated covariates if performing ML
logistic regression analyses. As shown in Figure 33 for the PF analysis, the log p-values
were essentially unreliable using maximum likelihood logistic regression. FEV values were
correlated with the diagnosis of severe pulmonary function because the FEV measures
part of the diagnostic criteria. Firth regression requires considerably more computational
resources, but is highly recommended in analyses with covariate correlation.
Clinical and demographic covariates were used to build a model predicting the pheno-
type; therefore, the bias generated from unaccounted degrees of freedom in the secondary
regression analysis was likely unsubstantial. The results from this variable selection analy-
sis, which served to reduce error in the resulting models, were more consistent with expected
distribution of p-values than ML regression. A penalized likelihood estimator better controls
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Figure 35. Gene set network for one of the top models. Three out of the six nonzero coefficients
were connected using IMP.
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errors when any correlation is present in the data.
Previously, authors of the dbGaP cystic fibrosis dataset published a study identifying
DCTN4 as a likely candidate gene modifier of PA infection using only the phase I data from
this study. The authors used an additive rare variant threshold approach (RVT1) approach
with a minor allele frequency threshold of 12.5% [119, 148]. After Bonferroni correction,
DCTN4 was significantly associated with chronic infection (adjusted p-value 0.025). Twelve
out of 43 cases in the phase I data had a missense mutation in DCTN4 [119]. In the PA
analysis using only nonsynonymous variants described in this thesis and all phase I and phase
II individuals, DCTN4 had 4 loci. Sixteen variants were present in cases and 10 variants
were present in controls (p-value = 0.3349, unadjusted for multiple testing). The results are
likely not replicated in our study because the sample size was doubled by including phase
2 individuals, different minor allele frequency cutoffs were used, individuals were excluded
that did not cluster with European descent populations, and potential noise contribution
from neutral variants.
The pathway analysis and elastic net analysis did not yield any exceptional results.
However, an important lesson can be learned. Noise contribution and variants of opposite
effect have been discussed many times in this thesis (Chapter III and Chapter IV) and
ultimately reduce power to identify true associations. Pathway analyses, such as the one
presented above, have increased noise and most likely have increased numbers of variants
with opposite effect. There are more variants included in the bin analysis, since multiple
gene bins are collapsed into one pathway bin. But more importantly, pathways have known
positive and negative regulators that can impact downstream function. A missense variant
upstream in a negative regulator might increase overall function of a particular pathway,
but a similar variant elsewhere could have a different effect. Therefore, until better variant
selection methods are available for BioBin, pathway analyses utilizing burden tests are
unlikely to contribute new information to low frequency variant analyses.
An alternate to the burden test or a machine learning technique is preferable for network
analyses. The potential for pathway analyses using nonburden tests is somewhat better since
these tests allow variants to be binned together even if the direction of effect is different
among variants. Alternatively, variants binned in a similar way will allow tools such as
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elastic net algorithms to build effective models from the data. This approach also benefits
from the flexibility to add common variants to analyses. The elastic net models produced
from the PA analysis do have some relationship with cell cycle regulation, but the fact that
this model was not replicated in each cross validation decreases the likelihood it has any
significance to the PA phenotype.
Conservative correction for the total results of all conducted analyses would eliminate
all significant results. In previous sections where multiple test correction has been men-
tioned, the p-values were corrected for only the test performed within the context of a
single analysis. For example, if a single bin analysis resulted in 15,000 bins, the Bonferroni
correction would only account for those bins, not for every 15,000 bins created for additional
parameters (weight testing, etc).
Lastly, most of the results discussed in this chapter were not significant after a multiple
test correction. This could be related to sample size and/or the stratification introduced
by multiple sequencing technologies, three separate exome capture kits, and multiple col-
lection/sequence sites. However, the type I errors were well-controlled and the results could
be prioritized for follow-up studies. Several of the bins in the PA gene analysis were par-
ticularly interesting in the context of cystic fibrosis disease, the CFTR gene, and chronic
Pseudomonas aeruginosa infection.
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CHAPTER VII
CONCLUSIONS
To explain additional phenotypic variation in common complex disease, it is imperative
to consider genetic variation beyond common single nucleotide polymorphisms. Rare vari-
ant analyses are appealing since effect sizes are potentially larger and increasingly available
in next generation data sets. However, to improve power, one must consider groups of
rare variants with similar properties. The most powerful application of collapsing methods
groups detrimental variants with other detrimental variants to effectively “build” a de-
tectable signal. Alternatively, the least powerful application of a collapsing method would
group variants with opposite directions of effect or include a significant number of variants
that contribute to noise but no meaningful signal. BioBin is a novel collapsing method that
uses allele frequency data and biological information to bin rare variants.
BioBin is unique because it is driven by a powerful database of biological/computational
knowledge, does not require any one explicit statistical paradigm, and provides bins with
direct interpretations of biology. The user can easily test complicated and interesting hy-
potheses on many features. LOKI provides access to integrated biological knowledge (path-
ways, groups, interactions, ECRs, regulatory regions, etc.), which is valuable to researchers
that do not want to spend considerable effort to combine this knowledge manually. Ad-
ditionally, the output of BioBin can be subsequently analyzed using the association test
most appropriate for their specific scientific question. For any given bin analysis, many
statistical tests including those from other published collapsing methods can be applied to
BioBin output.
In this thesis, the benefits for studying low frequency variants and the advantages of
using biological knowledge from BioBin have been outlined. In Chapter II, the properties
of low frequency variants and their potential contributions to heritability are described.
In addition, multiple published methods to study low frequency variants are reviewed.
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Chapter III provides a thorough overview of the BioBin software and relevant analysis
parameters or options. Extensive simulation studies testing BioBin and its various weights
and statistical tests are presented in Chapter IV. Chapter V chronicles a study of population
stratification in low frequency variant bins using Phase I 1000 Genomes data. Lastly,
Chapter VI contains demonstration analyses from two applications of BioBin to natural
data sets.
Because of the technological revolution resulting in increased available sequence data
and available biological knowledge, BioBin will become an even more useful analysis tool.
The ability to quickly form and test unique, interesting, and biologically relevant hypotheses
using aggregated low frequency variation will aide scientists in revealing hidden heritability
for common complex disease.
Evaluation of the analyses presented
Strengths of this approach
BioBin provides a tool for researchers with insurmountable data sets to utilize vast biological
knowledge for hypothesis generation. BioBin is a novel automation of binning analyses that
provides limitless flexibility. Users are able to bin at many levels of information: introns,
exons, genes, pathways, regulatory regions, and multiple other combinations. The Library
of Knowledge Integration (LOKI) database provides an assortment of established publicly
available databases to guide binning. The structure of LOKI also allows users to import
additional or external knowledge sources to satisfy individual binning needs.
Binning methods increase power over single low frequency variant association tests.
BioBin reliably identifies regions or collections of variants with differences in low frequency
variant distributions associated with the outcome of interest. It also affords users the ability
to perform complex filtering and weighting to increase the power to detect association for
any given bin.
Unlike other available methods, BioBin software is not restricted to any particular sta-
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tistical test. Users are able to apply burden and nonburden tests and machine learning
methods to BioBin output. This flexibility encourages users to identify and utilize statisti-
cal tests that best fit their data and hypothesis.
Limitations of this approach
In many cases, binning approaches are underpowered to detect true associations. Although
filtering and weighting approaches are available in BioBin, more work is needed to overcome
noise contributed by neutral variants or diminished signals from many variants of opposite
effect (i.e.., detrimental versus protective effects). In the implementation described in this
thesis, BioBin is limited by known biological knowledge. For example, the user is not able
to filter variants beyond lists of variants in known databases (e.g. 1000 Genomes Project
database), currently available prediction algorithms (e.g., SIFT or PolyPhen-2), or custom
knowledge files. Nonburden tests or additional methods of filtering should be added to the
binning analysis pipeline to overcome this loss of power.
Another limitation of using sequence data are genome reference. Variant calling format
(VCF) files are a common output from next-generation sequencing studies and are the
standard input file for BioBin. These files essentially contain all variation with respect
to the human reference genome. In theory, variation with respect to some standard is
exactly what should be compared in a bin analysis. In reality, the absence of a variant
with regard to the reference sequence and thus absence from a VCF file can also be due to
missingness (failed to meet quality standard to call variant with confidence) or off-target
sites (not within target region of exome capture kit). This problem will only be alleviated
when projects routinely sequence high depth of coverage (> 30x) and consistent capture
technology is used throughout the study.
The foundation of the BioBin approach is ultimately based on base pair proximity and
biological knowledge. Using BioBin implies that a collection of rare variants from a pre-
defined region confer an increased odds or risk of the phenotype of interest. For example,
causative low frequency variants within a gene increase the odds of developing schizophre-
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nia. Regardless of feature, every bin generated collapses variants based on contiguous
genomic coordinates. Of course, this limits the user to identifying collections of variants
defined proximity in genomic space, though this may not correspond to biological function
(interregion bins).
Lastly, the biggest limitation of any binning approach is data quality and size. In order
to reliably identify meaningful associations, artifact signals causing false positive associ-
ations must be smaller than the signal of interest (i.e., favorable signal to noise ratio).
Current study designs have not afforded this opportunity. In efforts to progress genomic
research and be considerate of costs, many studies combine samples from multiple plat-
forms/sites/ancestral backgrounds to increase power to study rare variants. Unfortunately,
these studies suffer from stratification due to ancestry, imprecise phenotyping, site-specific
sequence technology, differing target capture kits, and ambiguous/inconsistent data pro-
cessing pipelines. In addition, larger sample sizes are needed to establish reliable allele
frequency calculations and increase the number of binnable variants.
BioBin is reliable at detecting bins with differences in low frequency variant burden;
however, many times those differences are because a disproportionate number of controls
were sequenced with a different technology or capture kits. Due to the process of locus
selection, BioBin is sensitive to data quality and stratification. Statistical results from
BioBin output can be misleading if confounding factors are not considered and/or prevented.
Binning considerations
Study design
Good study design is critical in low frequency variant studies. Do et al. considers sample
selection to be the most critical component in exome-sequencing studies [6]. It is important
to catalogue potential samples and consider the most relevant study design:
1. Population samples
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2. Case/control studies
3. Families segregating Mendelian traits
Since the cost of sequencing is still quite expensive, researchers must carefully select
the study design and samples to be sequenced. In most cases, it is beneficial to focus on
extreme phenotypes [6].
Another consideration in sample selection is ancestry. The geographic distribution of low
frequency variants is highly dependent on ancestry; refer to Chapter V for more information
about ancestral differences in low frequency variant burden. Extreme care must be taken to
accurately match case and control groups in low frequency variant studies [6]. It is relatively
easy to incur false positive results due to population stratification and convenience control
samples most often are not the best matched controls. Unfortunately, it is unclear that
principal components can reliably and adequately adjust for population stratification in
low frequency variant studies.
In addition to carefully matching cases and controls for ancestry, it is imperative to apply
strict guidelines for the handling of case/control samples. Bias and type I errors can easily
result from study designs that sequence and process samples differently: sequence tech-
nology, sequence site, and variant calling pipelines. Although it is currently prohibitively
expensive, sequence studies will be more reliable when samples can be sequenced in dupli-
cate and perhaps on more than one technology or at more than one site. Concordant data
will enhance the accuracy of the analysis results.
Considering all of these recommendations, the ideal study for a BioBin analysis would
include at least 4000 extreme phenotypic cases (N=2000) and controls (N=2000) from
a single cohort study of similar ancestry. The phenotype should have well established
heritability. Thousands of samples are needed to establish reliable allele frequency estimates
generalizable to the sample population. Careful sample selection with regard to phenotype
and ancestry will increase the power of finding an association and decrease potential error
inducing noise. To identify the majority of variants with high specificity, filtered raw reads
should have at least 20x coverage at 80-95% of the sequence [6]. In an ideal study, each
sample would have whole-genome sequence data with a mean depth of coverage greater than
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or equal to 50x. At this level of coverage, the number of variants identified is less correlated
to depth of coverage [6]. Samples would be sequenced and processed at the same center
with nominal error rates. Whole genome sequence is preferred because it provides many
more avenues of discovery outside of coding regions. Higher mean coverage and controlled
sequencing and processing reduces the number of errors and potential stratification in the
data. The larger sample size and carefully phenotyped samples will increase the power of
finding true associations.
Replication in rare variant analyses
Statistical replication is a critical step to validate genomic study results. Most commonly,
replication is performed in a similar but independent dataset and the replicating signal
must have the same direction of effect in the same SNP or a SNP in very high LD with
the originally associated SNP [149]. This is often referred to as a “signal replication” since
association with any tag SNP represents the same signal.
Others hold the stringent view that a signal must be detected in the same SNP to be
considered a true replication; in this text defined as a “strict replication.” In common
variant association tests, which hinge on tag SNPs being in high LD with other common
variants, strict replication is not practical. For example, SNP1 and SNP2 are in very high
LD with each other. In a published study, authors only investigated SNP1 and found it to
be associated with phenotype X. If a second group of researchers published an association
between phenotype X and SNP2, this would not be considered a replication using “strict”
replication guidelines. Since common variant studies utilize SNP-tagging for genotyping
and association analyses, it is impractical to believe that results from a statistical test prove
definitive causation. Most putative SNPs with a common allele frequency can be accurately
tagged by more than one tag SNP. It is also impractical from a genotyping standpoint.
Platforms vary in genomic coverage and strict replication across two studies may not be
possible based on available genotypes. If constrained to strict replicate identification, many
signal replications will be missed. However, in rare variant analyses, which are most often
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in low LD or in very low frequency haplotypes, strict replication is more applicable.
In current literature, rare or low frequency single variant replications generally adhere
to the definition for strict replication. Guey et al. detail steps for replication in low
frequency analyses. The authors suggest first detecting an association in extreme phenotype
samples, and then replicating in a similar population or cohort using random sampling.
The extreme phenotypic sampling allows for variant prioritization, but also suffers from
“winner’s curse” similar to observations made from GWAS [149, 150], where the resulting
association signals in an extreme phenotypic sample study are often overestimated. To
assess the true effect size, the prioritized variants must be assessed in a randomly sampled
population of similar ancestry to the original sample. In addition, to accurately state
that a variant was replicated or not replicated, the replication dataset must be adequately
powered to detect an association [149]. For researchers seeking strict replication of rare
variant associations, data sets must be quite large [48, 150].
The concept of strict replication can be applied to common and rare single variant
analyses; however, for binned analyses the interpretation of replication is somewhat less
clear. To illustrate, consider the following example: GeneA bin is significant after primary
analysis. Researchers want to replicate the finding in a similar independent data set of
adequate size for single variant associations. If there were seven variants in the GeneA bin,
how many would have to be significant in single variant association tests to be considered a
replication of the GeneA signal? If only one variant replicated, could this still be considered
a replication of the GeneA signal? If the direction of effect changed for one variant compared
to the original direction of GeneA, would this diminish support of replication? If a bin
analysis was repeated and GeneA was significant with the same direction of effect, is this
adequate evidence for replication? What if the significant GeneA bin in the replication
set had only a subset of variants found in the original sample? Lastly, how could strict
replication be interpreted if there were epistatic interactions between variants in the bin?
Replication for bin analyses do not the follow the same interpretation as single variant
analyses. Variants with opposing directions of effect can (unfortunately) fall into the same
bin. Completely neutral variants are quite commonly binned with variants that contribute
to an association signal. Therefore, it would be illogical to require every variant in a
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significant bin to have an individual significant association in a replication study. It would
also be insensible to determine that every significantly associated signal must be the same
direction of effect as the original associated bin. This would require the exact same variants
to be found across multiple sequencing studies, no more and no less. This contradicts a
major benefit of binning studies, allelic heterogeneity. The idea behind rare variant binning
analyses is not that a single variant causes every instance of a studied phenotype, it is that
a collection or group of variants occurring in a functionally similar manner can manifest as
similar or the same phenotype. Secondly, variants contributing only noise to the original
signal should not necessarily be present again in the replicating signal. There may be new
neutral variants or only a subset of the original neutral variants in the replication results.
This change does not affect the interpretation of the replication.
Another complicating factor is linkage disequilibrium. Some variants in bins will be a
part of rare haplotypes in the same bin. A single bin could contain multiple haplotypes
and/or independent variants. Therefore, the application of signal replication can not be the
gold standard in binning results replication.
One last definition for replication could be considered in low frequency bin analyses,
functional replication. Essentially, what evidence can be found in a second independent
sample to support replication that results in a similar functional outcome? In the example
above, GeneA was significant in the original data set and researchers were seeking statistical
replication of this signal. In a replication set, any subset or expanded set of loci in GeneA
with a significant association supports functional replication. This could be from strict
replication from single variant associations, signal replication from haplotypes found within
the bin, or from bin replication. One particular challenge of functional replication is data
quality and interpretation. For example, functional replication of a single low frequency
variant requires larger sample sizes. Functional replication of a bin analysis requires a
cohort of similar ancestry, careful phenotyping, and adequate sequencing (depth of coverage,
consistent technology, etc). These are challenging for a research team, but are becoming
more common in the literature.
As larger data sets become available, replication will be important to validate binning
studies which are currently underpowered and potentially suffer from “winner’s curse.”
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While strict validation is most likely the gold standard (second only to molecular validation),
it is important to consider the context of binning analyses. Binning analyses focus on
functional units of information, e.g. low frequency variation in GeneA leads to phenotype
X. Variation within a bin can be neutral and variants with opposite effects can be binned
together. Follow-up analyses can include: single variant associations in large data sets,
haplotype analyses in large data sets, further binning analyses, or biological replication in
in vitro or in vivo systems. Each of these provide useful evidence for functional replication.
Future improvements to BioBin
Binning
Accurately and precisely binning variants that contribute to a signal, while minimizing the
inclusion of variants that only contribute noise, will increase the likelihood of detecting an
association. This is currently performed using filtering methods, such as removing variants
found in publicly available databases collected from “healthy” individuals or binning only
nonsynonymous or predicted damaging variants. Other methods use “step-up” approaches
or “sliding windows” to intermediately test the strength of the association signal, and prune
out variants that do not positively impact the strength of association [49, 54].
Improved binning should be more stochastic in nature, less reliant on databases of
“healthy” individuals and ultimately not limited to coding regions. A future step could
include using machine learning techniques such as random forest or evaporative cooling
implementations to prioritize variants that are most likely to contribute to an association
signal. Machine learning algorithms can guide the user to rank and ultimately select which
variants in a bin to keep and which should be dropped before performing a statistical
test [127]. The obvious potential hurdle is the computational resources needed to perform
this analysis, and deciding whether it should be performed on all low frequency variants or
separately for each bin of variants. Likely, the latter will be more informative since a single
variant can affect genes and pathways differently. Future low frequency variant analysis
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pipelines should creatively consider new methods to filter in/out variants to build the most
powerful association signal.
Novel statistical tests
Lastly, new statistical tests are needed to broaden the options available for low frequency
variant testing. Currently, if successful filters are applied and variants contributing to
the signal are in the same direction, burden tests are most powerful. If variants have
different directions of effect or varying effect sizes, nonburden tests are more powerful.
Some published statistical tests are designed for case-control studies, others do not allow
for covariate adjustment. There is a need for unbiased testing to critically evaluate the
effectiveness of each test on multiple versions of simulated data. It is unlikely one test is
superior in every scenario. In addition, new statistical tests are needed to better evaluate
small sample sizes and ignore variants that contribute to noise. Given the variety of tests
available and lack of analytical standards, users should carefully test type I error and power
in simulations for new statistical methods.
Future of rare variant analyses
Data integration and complex modeling
Although low frequency variants have frequently been published to explain additional her-
itability and resolve loci for Mendelian traits, low frequency variants most likely do not
act independently in the genomic variation spectrum. Similar to the era of GWAS, after
single variant association testing did not explain all of the heritability of a trait, researchers
began to search for epistatic interactions and build more complex models in an effort to
glean more information from the data. The same will be done in next-generation sequencing
data. Once the novelty of significant low frequency variant associations has been exhausted,
researchers will reconsider the complexity of biology and variation in the genome. Methods
for rare variant analysis should be easily adaptable to data integration techniques.
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Rare variant interactions
Statistical interactions between rare variant hits are also likely to contribute to heritability.
In low frequency analyses, the user often focuses on a genomic unit, usually a gene. If
binned together, epistatic interactions between rare variants can be captured within the
same bin (in many burden and nonburden tests). However, low frequency variants between
genes in a pathway and/or other types of “-omic” data can act in a non-additive manner
to affect the trait or phenotype of interest. Additional work should be done to implement
a pipeline to search for such interactions.
Combining common and rare variants
Currently, a few methods allow users to combine common and rare variants for analysis [21,
37, 49]. Models can be built to expand bins to include both common and rare variants or
create rare variant bins and combine with common single variant analyses [5]. Similarly,
algorithms such as Lasso could be used to select potentially important parameters in a
model [127]. Further work should be done in developing these pipelines since it is likely
that rare and common variants act in concert to affect or potentially cause a phenotype.
“Omic” modules
The most important future direction for low frequency variant analyses is data integration.
Data integration is the structural foundation needed to combine common and rare variants,
test interactions, and perform many other analyses that more closely resemble the true
mechanisms of biology. Biofilter, a tool developed in the Ritchie lab is currently being
expanded to build “omic” modules, an algorithm that will enable multiple types of genetic
data to be integrated. For example, if a user has methylome data, transcriptome data,
sequence data, and environmental variables, the extension of Biofilter will be able to build
modules based on relationships in the data. Consider the tumor suppressor gene CDH4
as an example, the center of the module is established by the DNA genomic location of
the gene, CDH4 is located at chr20:60,074,477-60,515,673 [71]. All other links between
data and CDH4 will map back to these coordinates. Links would be established to include
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common variants and low frequency variant bins in or nearby CDH4. Biofilter would map
relevant data to the root of the module (genomic location), i.e. hypermethlyation patterns
on the CpG island overlapping CDH4 promoter [151], pertinent expression data (for CDH4
and known regulatory elements), and environmental variables that relate to function in this
region.
The CDH4 “omic” module describes the data integration component of future analyses.
The next step will be to use these relationships to build testable models with machine
learning or regression techniques. To build models, one must consider relationships within
a single “omic” module or alternatively expand the search space using a variety of LOKI
sources. For example, a user might want to create pairwise interaction models between all
of the elements in the CDH4 module as well as models between all of the omic modules
involved in the cell adhesion molecule pathway [62]. This could be accomplished using
neural networks that will initially include all of the data in the relevant “omic” modules,
build multiple neural networks, and evaluate phenotype prediction power from generated
models [152]. This data integration/machine learning pipeline is advantageous because it
reduces the search space for model creation, allows for nonlinear models to be built, and
better estimates the complexity of biology.
Summary
BioBin is a novel method to collapse low frequency variants based on biological knowledge.
There are many available options in BioBin that can be configured to answer a variety of
scientific questions. Although, there are still challenges in the field of genomic research,
particularly with regard to sequence data consistency and quality, there are exciting op-
portunities to use collapsing methods such as BioBin to explore more complex biological
process using data integration and advanced modeling.
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